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Private practitioners are frequently the first point of healthcare contact for patients with 
tuberculosis (TB) in India. However, inappropriate TB management practices among private 
practitioners may contribute to delayed TB diagnosis. As new TB diagnostic tests are developed 
and the national TB control program seeks to beter engage the private sector, it is important to 
understand pathways to TB diagnosis in urban India. 
 
Design  
A cross-sectional study was conducted among patients and practitioners in Chennai city from 
January 2014 to February 2015. Patient participants were diagnosed with TB in the private sector 
and referred for TB treatment through a public-private mix program in Chennai. Practitioners 
practicing in the private sector, who saw at least one TB patient per year, were randomly selected 
from both the general community and a list of practitioners who referred patients to the public-
private mix program. Cross-section interviews were conducted with 289 patients and 228 
practitioners using standardized questionnaires.  
 
Results 
Among 212 patients with pulmonary TB, 90% first contacted a formal private provider, and 78% 
were diagnosed by the first or second provider seen after a median of three visits per provider. 
Median total delay was 52 days (Mean 69). Consulting an informal (rather than formaly trained) 
provider first, was associated with an increase in risk of prolonged total delay >90 days (aRR 2.5, 
95%CI: 1.3-4.5). Among 228 private practitioners, only 52% of practitioners sent >5% of patients 
with cough for TB testing, 83% used smear microscopy for diagnosis, and 22% notified TB cases 
to authorities. For new patients with pulmonary TB, 30% of practitioners reported referring al 
	  
	   ii 
patients for treatment, while 70% (160/228) listed 27 different regimens; 78% (125/160) of these 
prescribed a regimen classified as consistent with ISTC. Under half (48%, 110/228) of al 
practitioners utilized any point-of-care (POC) tests in their clinics. Providers using POC tests 
were more likely to work in hospitals (56% vs. 43%, P=0.05) and less likely to be chest 
specialists (21% vs. 54%, P<0.001). When asked about using a hypothetical, novel POC test for 
TB that was accurate, took 20 minutes, and required no equipment, only half (51%, 117/228) of 
al providers would use the test in-house.  
 
Conclusion 
Even among patients seeking care in the formal private sector in Chennai, diagnostic delays are 
substantial. TB management practices in India’s urban private sector are heterogeneous and often 
suboptimal. Novel strategies are required to engage private providers and integrate new 
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Chapter I: Introduction 
 
Tuberculosis and the Burden in India 
Although tuberculosis (TB) is a curable disease, it remains a major public health problem 
throughout the world. TB is the second leading infectious disease cause of death after human 
immunodeficiency virus (HIV) worldwide.1 In 2013, there were 9 milion incident cases of TB 
and 1.5 milion deaths from TB according to the World Health Organization (WHO).1 
In India today, it is estimated that two deaths occur every three minutes from TB.2 India 
had an estimated 2.1 milion incident TB cases (171 per 100,000) occurring in 2013; a TB case 
burden that accounts for 24% of the world’s incident cases.1,2 WHO ranks India as the top country 
for TB burden with its total population over 1.2 bilion people, 2.6 milion prevalent TB cases 
(211 per 100,000), and 240,000 TB-related deaths (19 per 100,000).1 Additionaly, 2.2% of al 
new cases and 15% of al retreatment cases in India were diagnosed with multidrug resistant TB 
(MDR TB) in 2013.1,3 India also ranks as the top country accounting for 31% (2.9 milion) of the 
global “missed” TB cases that are either not diagnosed or diagnosed but not notified to the 
national TB program.3 
 
The Indian Healthcare System: Role of the Public and Private Sectors 
The Indian Healthcare System is complex and heterogeneous.4,5 Disease-specific, vertical 
health programs play a central role in strengthening components of India’s health system by 
sharing human and material resources, increasing demand for health services, and encouraging 
civil society’s involvement in service delivery.6 Vertical programs, such as the Government of 
India’s Revised National Tuberculosis Control Programme (RNTCP), also aid in improving 
patient confidence and perceptions in facilities for diseases of high public health significance.6 
The RNTCP is located within the Department of Health and Family Welfare. It is sponsored by 
the central health ministry and receives litle (<1%) outside funding support from international 
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donors for its health resources.6 The vertical design and structure of the RNTCP are more 
functionaly integrated with the Indian health system, aiding its contribution towards 
strengthening the overal health systems.6,7 
In 1998, the RNTCP began implementation of the WHO’s global TB control strategy of 
directly observed therapy short-course (DOTS) and expanded to countrywide coverage by 
2006.8,9 The RNTCP currently provides decentralized access to free diagnostic and treatment 
services for patients with TB in approximately 13,000 sputum smear microscopy centers and 
650,000 DOTS centers within the public healthcare system.2 Although this access to public 
healthcare is widely available, up to 80% of individuals with a cough lasting more than two 
weeks first seek care from private healthcare providers.4,5,9–12 These private providers include 
both qualified and unqualified providers and practitioners of alternative health systems that 
outnumber qualified, alopathic doctors in some urban setings.4,5,13 There is evidence that up to 
25% of individuals classified as alopathic doctors working in the private sector have no medical 
training and thus are unqualified practitioners.4,5,13,14 Further, while the Government of India has 
made TB case notification mandatory to improve case detection and TB control efforts, private 
practitioners rarely comply and notify the government of their patients with TB.15 
The RNTCP’s National Strategic Plan for 2012-2017 aims to achieve “universal access” 
to quality assured TB diagnosis and treatment for al patients with TB by 2017.16–18 To achieve 
this vision, the RNTCP aims to reach the folowing targets: (i) early detection and treatment of at 
least 90% of estimated TB cases in the community; (i) screening of al re-treatment smear-
positive TB patients for drug-resistant TB and provision of treatment for MDR TB patients; (ii) 
HIV counseling and testing offered for al TB patients with linkage to HIV care support for those 
with HIV; (iv) successful treatment of at least 90% of al new TB patients and 85% of al 
previously-treated TB patients; and (v) RNTCP services extended to patients diagnosed and 
treated in the private sector.16 The RNTCP seeks to achieve these objectives by sustaining the 
program activities and achievements to date, and by extending the reach and quality of services to 
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al persons diagnosed with TB, including beter engagement of the private sector in partnerships 
for TB diagnosis.16 
 
Patients Accessing the Indian Private Sector 
Patients with TB in India often see multiple healthcare providers prior to obtaining a TB 
diagnosis. Frequently, patients with TB symptoms begin seeking advice from informal private 
providers, then seeking medical care from formal private practitioners, and eventualy end up 
geting free treatment under the RNTCP. 4,5,19–21 Thus, patients move from one provider to another 
until they are finaly diagnosed with TB and initiated on TB treatment after substantial delays 
since symptom onset.4,5,19 However, there is evidence that up to two-thirds22 of patients seek care 
and are treated exclusively in the private sector, these practitioners include formaly-trained, 
alopathic doctors and non-alopathic AYUSH (includes ayurveda, yoga and naturopathy, unani, 
siddha, homeopathy) practitioners13, and informal traditional healers, unqualified or unlicensed 
practitioners, and chemists or pharmacists who practice in the private sector. Even given its 
prominent role in TB patient management, litle is understood about the pathways to diagnosis 
and delays to TB treatment among these patients in the private sector.4,20,23 
With litle colaboration across the health sectors, navigating the Indian health system can 
be chalenging for individuals with TB-related symptoms. A household survey in Chennai 
showed that 60% of the individuals with a long-standing cough first went to a private practitioner 
for care.24 An older study previously reported that as many as 67% of patients are diagnosed and 
started on TB treatment by private healthcare providers and remained with the private sector, 
while 34% changed to the public sector within the first six months.14 More recent research from 
Mumbai determined that only one-third of the private practitioners surveyed referred their 
patients with TB to government services for treatment.10 Seeking care from a private practitioner 
as the first point of care is more common among patients living in urban areas, who are literate, 
and earning an income greater than 2,000 rupees (approximately US$31.00) per month.4,11 Given 
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this heavy private sector involvement, understanding the diagnostic pathways among patients 
who access and are ultimately diagnosed and treated in the private sector (without accessing the 
RNTCP) is critical to TB control in India. 
 
TB Diagnosis in India: Importance of Diagnostic Tests for TB Control 
Early diagnosis and effective treatment of TB are critical to mitigate the burden of TB 
transmission1; however, the most widely used TB diagnostic test globaly, sputum smear 
microscopy for acid-fast bacili, is over 125 years old and routinely fails to detect half of al TB 
cases.25–27 Based on a negative policy recommendation from the WHO, in 2012 the Indian 
government banned the manufacture, sale and distribution of sero-diagnostic test kits for 
diagnosis of tuberculosis.3,28–32 As a result, the diagnostic landscape in India is changing with the 
availability of novel automated TB diagnostic technologies, such as the Xpert MTB/RIF assay 
(Xpert) and the line probe assay. Owing to its high sensitivity to detect TB and rifampicin 
resistance in two hours, Xpert is recommended by WHO for diagnosis of individuals at risk of 
having MDR-TB or HIV-associated TB and as a folow-on test to microscopy.3 Unfortunately, 
other serological tests (e.g., QuantiFERON Gold In-Tube), designed for diagnosis of latent TB 
infection, are also being used for active TB diagnosis in India.33–35 
In accord with the RNTCP’s National Strategic Plan to achieve “universal access” to TB 
diagnosis, the Initiative for Promoting Affordable Quality TB tests (IPAQT) has made WHO 
endorsed tests more affordable in the private sector, with an effort to address the gap left by the 
ban on serological tests.3,36 NGO-led models24 and Private Provider Interface Agency projects in 
select cities37 are also working to engage private practitioners in guideline-based TB care. 
Nonetheless, for the utility of new diagnostics to be realized, the current practices, needs, and 
chalenges of private providers in TB care must be addressed. To realize the goal of universal 
access to TB care, it is important to understand the patient pathways where delays and missed TB 
diagnoses occur in order to implement diagnostic algorithms to reduce these delays.21 
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Patient Pathways to Care for TB 
Due to the complicated pathways to obtain care for TB in India, many patients experience 
a delay of two months or more from symptom onset to TB diagnosis and treatment 
initiation.4,5,20,23 In a study conducted in Delhi among patients that first sought care in the private 
sector, 25% of patients saw four medical providers for TB-related symptoms prior to atending an 
RNTCP DOTS center for treatment.5 In their complex pathways to care, 62% of patients with 
TB-related symptoms initialy accessed health services from an informal private practitioner, 33% 
from a qualified private medical practitioner, and 7.4% from a retail chemist (pharmacist) (Figure 
1).5 Other studies of patients accessing the RNTCP TB services have reported mean delay 
durations up to five months from symptom onset to treatment initiation5, and mean treatment 
delays from patient diagnosis with TB to initiation of treatment ranging from one to eight 
days4,5,23, but up to 128 days in rural areas.51 Factors associated with delays in diagnosis and 
treatment initiation in the public sector include: previous treatment, seeking a second opinion, 
drug delivery delays, and absence of TB diagnostic services in the local health facility.5,11,12,23,51 
Qualitative research has found that during this process of care seeking with multiple providers, 
patients lose considerable amounts of money and time as they are referred to private labs for 
multiple diagnostic tests to rule out non-TB diseases such as typhoid and malaria fevers.52,53 
Patients must then return to the private practitioners for interpretation of the diagnostic tests due 
the relationships between labs and providers, further contributing to their healthcare expenses. 
This arrangement can lead to distrust among patients causing them to switch providers, seek 
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This figure, published by Kapoor et al.9, ilustrates the pathways taken by patients who were 
treated for TB under the RNTCP in Delhi, India in 2012. Al of the patients initialy sought care 
from informal and formal private providers with long delays before TB treatment initiation. 
Among these patients, 25% saw four healthcare providers prior to atending an RNTCP DOTS 
Center. Al patients were sampled from the public sector where they were eventualy treated at 
RNTCP DOTS Centers. 
  
 
Figure 1.1. Pathways undertaken by patients to reach the RNTCP (DOTS) Facilities in 
Delhi, India. 
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Prolonged total delays to diagnosis after TB symptom onset occur frequently among patients who 
first seek care in the private sector, alowing for ongoing TB transmission in the community 
during the total symptomatic time.4,20,23 Increased delays from symptom onset to treatment 
initiation are also associated with seeking additional medical counsel or second opinions, female 
gender, site of TB disease, and absence of local diagnostic services.4,5,11 Additionaly, multiple 
visits to a private practitioners required prior to TB diagnosis due to lack of TB symptom 
screening knowledge also contributes to prolonged diagnostic delays.4 
It is widely recognized that TB control in India wil not be achieved without engagement 
of the private healthcare providers.16,33,54 By beter integrating the private sector with the RNTCP, 
it may be possible to reduce the time patients spend seeking a diagnosis after onset of 
infectiousness, thus decreasing the burden of TB transmission in the community. However, the 
actual usage of specific TB diagnostic tests, TB patient volumes, capacity to achieve rapid TB 
diagnosis, and practitioner characteristics associated with prompt and appropriate diagnosis in the 
private sector are not wel characterized.10,14,45 
 
Private Practitioners’ TB Diagnosis and Treatment Practices  
The current RNTCP guidelines for pulmonary TB diagnosis rely on outdated technology 
including chest x-ray as a screening tool and microbiological confirmation of diagnosis with 
sputum smear microscopy.38,39 Cartridge-based nucleic-acid amplification tests, such as Xpert, are 
recommended as a diagnostic test for children, persons with HIV-infection, and for suspected 
drug-resistance, but not for general diagnosis of pulmonary TB.16,38,40 However, a recent 
systematic review found that only half of the healthcare providers from both the public and 
private sectors tested patients with long-lasting cough for suspicion of TB, and just two-thirds 
used smear microscopy for patients with presumptive TB.24,41 
The existence of a significant private health sector (comprised of qualified and 
unqualified providers) in India that frequently serves as the first point of medical contact for 
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patients with TB-related symptoms is one of the reasons for low case detection rates, wherein 
practitioners frequently diagnose TB using inadequate diagnostic tests.1,33,41 For example, private 
healthcare providers commonly use serologic antibody tests to diagnose active TB in the Indian 
private sector, and inappropriate TB prescriptions are common. Poor treatment prescription 
practices are evidenced by the finding that only one third of private sector practitioners know the 
international standard treatment regimen for new patients with drug-susceptible TB.10,22,41 Given 
the reports of poor treatment outcomes and emerging drug resistance in India, these findings are 
particularly concerning, especialy in urban areas.41–44 
The RNTCP and the Indian Medical Association have adopted the International 
Standards for TB Care (ISTC) and recently published the Standards for TB Care in India (STCI) 
to support quality TB control practices.45–47 The ISTC include 21 standards of diagnosis, 
treatment, and other practices that describe a widely accepted level of TB care.45,47 The standards 
are intended to be complementary to local and national TB control policies that are consistent 
with WHO recommendations to promote effective engagement of al providers in delivering high 
quality care fore patients.47 Measures of adherence to the ISTC in primary care centers in rural in 
Uganda found that approximately 52% of patients received ISTC-adherent care for TB48, higher 
than a study in Indonesia reporting just 21% adherence in public health centers49, though stil 
inadequate for TB control. Nevertheless, the lack of adherence to the ISTC and STCI continues to 
be documented among private practitioners in India where adherence ranges from 11% to 94% 
for key standards, including use of sputum smear for persons with presumptive TB.10,22,45,50 The 
inadequate TB management practices reported among private practitioners contribute to delays in 
TB patient diagnosis, development of drug-resistance, and ongoing TB transmission.17,41,45 
 
Delays in Pathways to Diagnosis of TB  
Delays in diagnosis of patients with TB are a key driver of transmission worldwide 
and may be a reason why TB incidence has not substantialy declined despite global scale-up 
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of the DOTS strategy.1,4,55,56 Patients seeking care for TB-related symptoms can experience 
delays at any point along their pathway to TB diagnosis and treatment. The Conceptual 
framework of definitions of delays presented by Sreeramareddy et al. in a systematic review 
of delays in diagnosis and treatment of pulmonary tuberculosis in India evaluates the 
diagnostic process for individuals seeking care for TB-related symptoms (Figure 1.2).4 This 
framework provides a linear model of the intervals that define a patient pathway to care from 
the time of TB symptom onset to treatment initiation. Additionaly, an adapted framework for 
The Model of Pathways to Treatment developed by Scot et al. is presented here to understand 
the complex and dynamic nature of patient pathways through the Indian private sector (Scot 
Pathways Model; Figure 1.3).57 In the adapted Scot Pathways Model, time intervals may 
occur in any sequence between events with no starting point, including forward and backward 




The conceptual framework of definitions of delays characterizes the intervals from the time 
of TB symptom onset to diagnosis and treatment of pulmonary tuberculosis in India.4 This 
duration represents the total symptomatic time and period of infectiousness for a patient with 
TB. 
 
Figure 1.2. Conceptual framework of definitions of delays. 
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The Model of Pathways to Treatment by Scot et al.57 adapted for TB patients seeking care in the 
urban Indian private sector evaluates events occurring as features of the disease, patient, and 
health system. The framework ilustrates processes that occur within intervals of the pathway 
that lead to potential event outcomes.	  The interval time periods may occur in any sequence 
between events with no starting point, alowing for forward and backward movement, as a patient 
navigates the health system to obtain diagnosis of TB and initiate anti-TB therapy.	  
	  
	  
The large number of patients who access the private sector as their first point of 
healthcare for TB-related symptoms, and the practitioners who see them, represent a key 
population for intervention to reduce TB transmission in the community. These models 
provide insight into the potential impact of intervention strategies for TB control by 
identifying independent features and intervals of pathways to care where a reduction in delay 
may improve diagnostic and treatment outcomes. 
Figure 1.3: An adapted framework of The Model of Pathways to Treatment for Tuberculosis 
diagnosis. 
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Impact of Novel TB Diagnostic Tools: Scale-Up of Xpert MTB/RIF and Point-of-Care Testing in 
India 
Increased diagnostic capabilities to improve in TB case detection could substantialy 
reduce the gap between notified cases and estimated incidence, while also reducing 
diagnostic delays.1 The availability of a rapid, low cost, accurate diagnostic assay for TB that 
could be used at the point of care would be a major advance in efforts to reach the 2.9 milion 
“missed” TB cases in India.39 Such point-of-care (POC) tests offer rapid turn-around and 
communication of results to guide clinical decisions alowing diagnostic testing and folow-
up actions to be completed in the same clinical encounter.53 As TB control programs 
worldwide are beginning to prioritize molecular diagnostics that are more sensitive than 
smear microscopy58, it is imperative to consider implementation of tests for TB that could be 
deployed at the point-of-care.53,59 However, strategies for improving TB diagnostic practices 
in India need to be evidence-based and informed by data in the context of diagnostic 
pathways where they wil be used.60,61 
India has commited $100 milion to scale-up of Xpert within the country3, but the 
overal effect of implementing Xpert and other novel diagnostic tools wil ultimately depend 
on deployment to improve the timeliness of effective treatment initiation.60 Currently, India is 
using Xpert largely for diagnosing MDR TB among patients known to have TB rather than 
initial diagnosis of TB.3 A recent study of Xpert use in decentralized public health setings in 
India found a 33% increase in the proportion of presumptive pulmonary TB patients with 
microbiologicaly confirmed TB and a 39% increase in TB case notification compared to 
using smear microscopy for initial diagnosis.62 However, for Xpert and other POC TB 
diagnostics to reach those who need them, tests must be atractive, accessible, and practical to 
private practitioners who dominate the healthcare marketplace in India.37 
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Modeling analyses suggest that novel diagnostic tests can impact TB incidence in 
southeast Asia; however, their effect depends on sensitivity and the manner in which they are 
deployed.63 The management of HIV and malaria was transformed by the availability of low-
cost POC diagnostic tools, yet the need for POC tests for active pulmonary TB remains 
unmet contributing to delayed diagnoses that fuel the epidemic in high burden countries like 
India.21,59,64 Research into Xpert use as a POC test for TB has demonstrated feasibility in 
African setings65, but it remains a high-cost test that requires sophisticated equipment.64 
Further, the use of Xpert for TB diagnosis has not led to improvements in morbidity or 
mortality, though further research in additional setings is needed to determine the long-term 
impact65, though modeling analyses suggest its use may decrease community TB 
transmission.21,63 The urine lipoarabinomannan (LAM) lateral flow assay represents a simple, 
low-cost diagnostic test for TB that can be used at the point of care, but its niche use is 
limited to screening for HIV-associated pulmonary TB in patients with advanced 
immunodeficiency.39,66 Additionaly, other nucleic acid amplification tests are emerging in 
development pipelines building on the technology of Xpert, but with a range of options that 
alow for selection of tests that best suit local needs.67 In the Indian seting, these include the 
portable PCR-based Truenat MTB assay (Molbio Diagnostics, Goa, India) that is intended for 
use in peripheral setings.67,68 Nonetheless, an ideal, hypothetical, rapid test that can be 
deployed simply and closer to the point of care for active screening of TB in the private 
sector could have a projected 15% impact on reducing TB incidence.63 Thus, as the RNTCP 
invests in deploying TB diagnostic tests capable of same-day diagnosis such as Xpert, and 
NGO-led models work to increase test availability in private laboratories17,69, mechanisms of 
public-private cross-referral and regulation are essential to engage private practitioners to 
have a considerable population-level impact on TB in India.21  
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Conclusions 
The RNTCP’s plan for “universal access” to quality diagnosis and treatment for al 
patients with TB in the community recognizes the need to engage private sector providers in TB 
control efforts, to provide cost offsets to patients diagnosed and treated by private practitioners, 
and to improve national case notifications.69 Additionaly, as novel technology for diagnosis of 
active TB becomes increasingly available, it is expected to expand access to medical services, 
reduce delays in diagnosis, and improve health outcomes.70 However, these improvements may 
not have a substantial population-level impact on the TB burden in India if they are not matched 
by innovation in the health system. A critical element of implementing any novel diagnostic test 
is to evaluate the existing mechanisms of patient access, as wel as the capacity for, and 
acceptability of, the test among those healthcare providers who would be responsible for using 
it.39,53 In this context, several important unanswered questions include the folowing: 
(1) What is the impact of the first healthcare provider consulted on delay to diagnosis 
among patients diagnosed with TB in the urban Indian private sector? 
(2) What are the TB management practices among urban Indian private practitioners 
and how do these compare to the International Standards for TB Care? 
(3) What are the point-of-care testing practices and the priorities for novel point-of-care 
tests for TB among private practitioners in Chennai, India? 
A cross-sectional survey of patients accessing the private sector for TB diagnosis and 
practitioners who saw at least one patient with TB in the past year was conducted in Chennai, 
India in colaboration with the Resource Group for Education and Advocacy for Community 
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Chapter II: How do patients access the private sector in 
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Abstract  
 
Setting: Diagnosis and treatment of tuberculosis (TB) in India are characterized by heavy 
private-sector involvement. Delays to treatment remain poorly characterized among patients 
seeking care in the Indian private sector.  
 
Objective: To assess delays in TB diagnosis and treatment initiation among patients diagnosed in 
the private sector, and pathways to care in an urban seting. 
 
Design: Cross-sectional survey of 289 consecutive patients who were diagnosed with TB in the 
private sector and referred for TB treatment through a public-private mix program in Chennai 
from January 2014 to February 2015. 
 
Results: Among 212 patients with pulmonary TB, 90% first contacted a formal private provider, 
and 78% were diagnosed by the first or second provider seen after a median of three visits per 
provider. Median total delay was 51 days (mean 68). Consulting an informal (rather than 
formaly trained) provider first, was associated with a significant increase in total delay (absolute 
increase: 25.8 days, 95%CI: 9.9-41.7) and in risk of prolonged delay >90 days (aRR 2.5, 95%CI: 
1.3-4.5).  
 
Conclusion: Even among patients seeking care in the formal (vs. informal) private sector in 
Chennai, diagnostic delays are substantial. Novel strategies are required to engage private 
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Introduction  
Delays in diagnosis of patients with tuberculosis (TB) are a key driver of transmission 
worldwide.1,55 In India, where one thousand people die of TB every day, excessive delays often 
occur between the onset of TB symptoms, diagnosis of disease, and initiation of anti-TB 
therapy.1,2,4 Early diagnosis and effective treatment are critical to reduce TB mortality and stop 
ongoing transmission.1,4,17 The Government of India’s Revised National Tuberculosis Control 
Programme (RNTCP) aims to achieve “universal access” to quality diagnosis and treatment for 
al patients with TB by 2017.16 To realize this goal, it is important to understand where delays and 
missed TB diagnoses occur and how to implement diagnostic algorithms to reduce these delays.21 
 
India has a complex and heterogeneous healthcare system.1,4,5 The RNTCP provides access to free 
TB diagnostic and treatment services in the public sector.9 However, up to 80% of individuals 
with long-lasting cough first seek care from the private sector, where unqualified providers and 
practitioners of alternative health systems outnumber qualified, alopathic doctors.4,5,13,14 With 
litle colaboration across health sectors, many patients with TB see multiple healthcare providers 
(HCPs) as they first seek advice from informal private providers, then medical care from formal 
private HCPs, and eventualy get treated under the RNTCP.4,5,19–21 Other patients seek care 
exclusively in the private sector; yet, we know very litle about the pathways and delays to TB 
diagnosis and treatment among these patients.4,20,23 Although the Government of India has made 
TB case notification mandatory, this practice is rarely folowed by private practitioners.15 
 
Currently, the RNTCP seeks to beter engage the private sector in partnerships for TB treatment 
(a “public-private mix”, or PPM model), offering the opportunity to explore pathways to TB 
diagnosis among patients who seek care in the private sector.4,14,18 We therefore undertook a study 
	  
	   17 
to evaluate delays in TB diagnosis and treatment initiation among patients who were diagnosed 




This study was conducted in Chennai in Tamil Nadu state in India. Chennai was the sixth largest 
city in India with a population of 4.6 milion in 2011, making it the most densely populated city 
in Tamil Nadu.71 
 
Study design and study population 
In colaboration with the Resource Group for Education and Advocacy for Community Health 
(REACH), we conducted a cross-sectional survey of patients accessing the private sector for TB 
diagnosis. REACH is a non-governmental PPM organization established in 1999 operating in 
colaboration with Corporation of Chennai to involve private HCPs in the RNTCP.24 REACH 
operates four PPM centers located in private hospitals working with a network of private HCPs in 
Chennai to support patients with TB. In the REACH PPM model, private HCPs refer patients 
with TB to PPM Centers to receive free DOT under supervision of REACH staff.  
 
Sample selection and data colection 
We recruited patients who were diagnosed with TB and referred to REACH PPM Centers in 
Chennai by private HCPs (i.e., not referred by pharmacists or government/RNTCP practitioners). 
From January 2014 through February 2015, we consecutively enroled consenting patients from 
al four REACH PPM Centers and conducted interviews using a structured questionnaire. Al 
adult patients with pulmonary (PTB), extra-pulmonary, or drug-resistant TB receiving treatment 
for six months or less at a REACH PPM Center were eligible for interview. Trained study staff 
performed interviews privately at REACH PPM Centers or via telephone at the patients’ 
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discretion. The patient interviews colected information on patient socio-demographics and 
clinical TB disease; intervals between symptom onset, TB diagnosis, and treatment; and used 
multiple prompts to understand the characteristics, sequence and type of providers consulted. The 
type of provider and dates of symptom onset, health-seeking encounters, diagnosis, and treatment 
initiation were colected by patient recal using multiple questions and/or from patient treatment 
cards when available from the patient. Family members frequently accompanied patients during 
the interview though they were not the subjects of the interview. 
 
Definitions  
We utilized the conceptual framework proposed in a systematic review by Sreeramareddy and 
coleagues to shape our definitions of delay.4 Our primary outcome was total symptomatic time, 
or total delay, defined as the interval from patient-reported symptom onset to TB treatment 
initiation. We defined prolonged total delay as duration >90 days, which was the 75th percentile in 
our sample, and extremely prolonged delay as duration >150 days, which was the 90th percentile 
in our sample. 
 
For this analysis, we classified an HCP as any person or facility approached by the patient for 
relief from their health problem.20 Formal HCPs include alopathic doctors and non-alopathic 
AYUSH (includes ayurveda, yoga and naturopathy, unani, siddha, homeopathy) practitioners13 
with formal training who practice in the public or private sector. The public sector comprises al 
formal HCPs working in government facilities. The private sector includes al formal HCPs 
practicing in a private clinic or hospital, and informal HCPs including traditional healers, 
unlicensed practitioners without formal medical training, and chemists or pharmacists. Patients 
diagnosed in a private hospital who then began treatment at the REACH PPM Center within the 
hospital were counted as diagnosed by a formal private HCP. Patients diagnosed by a formal 
private HCP in a separate clinic and then referred to a REACH PPM Center for treatment were 
	  
	   19 
considered to have PPM as a separate, final provider. Patients were classified as having ≤2 visits 
per HCP if the number of visits was unknown. 
 
Statistical analysis 
We performed univariate analyses to assess differences in proportion for categorical variables 
using Pearson’s chi-squared and Fisher’s exact test. Among patients with PTB, we examined 
patient pathways to TB treatment by HCP type, sector, and sequence using the median 
[interquartile range]. We assessed differences in median total delay, measured continuously in 
days, using the non-parametric Wilcoxon test. We explored patient pathway characteristics 
specified a priori for differences in mean total delay using generalized linear models with a 
gamma distribution, identity link function, and robust standard errors. We adjusted for potential 
clustering of health-seeking behaviors by PPM Center location. We investigated risk factors for 
prolonged delay comparing patients with total delay >90 days in multivariable Poisson regression 
models with robust standard errors (as log-binomial models failed to converge).72 
 
Results  
Socio-demographic and clinical disease characteristics 
Among the 479 patients initiated on treatment through REACH PPM services during the study 
period, 289 patients were	  referred from private practitioners and thus eligible for the study. No 
patients declined the interview. Of these 289 patients interviews, the median patient age was 42 
years. The majority of patients interviewed were men (56%), literate (87%), employed (54%), 
and lived in households earning <8,000 rupees per month (52%, approximately US$130). There 
were 212 patients with pulmonary TB, among them 67% reported cough lasting ≥30 days prior to 
presentation to an HCP. Only 16% of patients were previously treated for TB, and 29% reported a 
family member having received TB treatment. (Table 1). 
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Health seeking characteristics  
Of al patients, 243 (84%) first sought care in the formal private sector (240 alopathic and 3 
AYUSH providers), 28 (10%) in the informal private sector (15 pharmacists and 13 traditional 
healers or other providers), and 18 (6%) in the public sector. Patients saw a mean of 2 HCPs prior 
to TB diagnosis; only 10% saw more than 4 HCPs. However, patients visited their first and 
second HCPs a median of 3 times each prior to being diagnosed with TB. For the first HCP, 
median distance traveled was one kilometer and median total cost incurred was 1000 rupees 
(approximately US$16). In univariate analysis, employment, cough duration, first healthcare 
sector consulted, first HCP type, number of HCPs seen, and total cost were significantly 
associated with total delay >90 days from symptom onset to treatment initiation. Cough duration, 
site of TB disease, and number of HCPs seen prior were significantly associated with total delay 
>150 days. (Table 1). 
 
Patient pathways to care for pulmonary TB 
Of 212 patients with PTB, we identified 34 unique pathways through the private sector to TB 
diagnosis and treatment (Figure 1). Over three-quarters (165/212) of patients were diagnosed with 
TB after two or fewer providers. Diagnostic tests performed included chest x-ray (57%), blood 
test (46%), sputum smear (31%), others (16%), and CT scan (13%). The majority (167/212) of 
patients sought care exclusively from formal private HCPs. Over one-quarter (60/212) of patients 
were diagnosed by the first provider accessed and then referred to REACH PPM for TB treatment 
for a median total delay of 50 days, and a median of 3 visits per provider as above. The median 
interval between health seeking encounters with the first and second HCP was 10 days [IQR 5-
30]. Only 5% (11/212) of patients first sought care in the public sector and were subsequently 
diagnosed with TB by a private HCP before being referred to REACH for treatment. Over half 
(119/212) of the patients reported the provider they first contacted was their contact for al 
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medical needs. Additionaly, 65% (138/212) of patients were not aware that free TB services 
were available at government health centers.   
 
Patient and Health system delays 
Among those with PTB, the median patient delay was 10 days (mean 25, range 0-339) from 
patient-reported symptom onset to first HCP contact; 23% waited >30 days to seek care after 
symptom onset. Median diagnostic delay from the first HCP encounter to confirmation of TB 
diagnosis was 28 days (mean 44, range 0-322). Median treatment delay from confirmation of TB 
diagnosis to TB treatment initiation was 2 days (mean 5, range 0-75). The median combined 
health system delay from first HCP contact to TB treatment initiation was 30 days (mean 46, 




The median total delay from symptom onset to TB treatment initiation for patients with PTB was 
52 days (mean 69, range 3-341). In adjusted analyses, patients who first consulted an informal 
HCP experienced a significant increase in mean total delay (mean increase: 25.8 days, 95%CI: 
9.9-41.7). Mean total delay also increased if patients sought care from >2 HCPs (20.3 days) or 
were unemployed (17.9 days). (Table 2). 
 
Predictors of prolonged total delay 
Among patients with PTB who first consulted the formal private sector, a longer mean patient 
delay was noted, while the health system delay was longer among patients in the informal sector 
(Figure 2). Mean total delay for patients who first sought care in the public sector was 66 days 
(95%CI: 39-94; median 64 [IQR 47-77), similar to patients accessing the private sector (mean 65, 
95%CI: 57-74; median 48 [IQR 31-82]). For patients who first sought care in the informal private 
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sector, mean total delay (96 days, 95%CI: 66-126; median 73 [IQR 63-111]) was longer 
compared to those seeking care in the formal private sector (difference in mean total delay: 31 
days, 95%CI: 14.2-47.6, P<0.001) and public sector (difference in mean total delay: 30 days, 
95%CI: 1.5-58.4, P=0.04). 
 
Nearly one-quarter of patients with PTB (46/212) experienced prolonged total delay >90 days and 
7% (15/212) experienced extremely prolonged delay >150 days. In adjusted analyses, patients 
who first sought care from an informal HCP had 2.5 times the risk of having delay >90 days 
compared to formal HCPs (aRR 2.5, 95%CI: 1.3-4.5) (Table 3). Additionaly, unemployment, no 
family history of TB, seeing >2 HCPs, and total spent with first HCP significantly increased the 
risk of delay >90 days.  
 
Discussion  
This study of patients diagnosed with TB in India’s private sector demonstrates that prolonged 
delays are more common among patients accessing informal, rather than formal, providers as the 
first contact in their pathways to care. Among patients with PTB, first seeking care from an 
informal provider is associated with an almost four-week increase total symptomatic time prior to 
treatment initiation. Although prolonged delays in diagnosis are often atributed to patients 
seeking care from multiple HCPs in the private sector, 78% of patients in this study were 
diagnosed with PTB by the first or second provider they saw after relatively few visits per HCP. 
Nonetheless, delays remain substantial even among those who only saw formal providers; 
patients had a mean of three visits prior to TB diagnosis and health system delay exceeding 40 
days, suggesting that even qualified HCPs may utilize non-specific or empiric therapies prior to 
testing for TB.  
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Our study is among the first to characterize patients diagnosed with TB in the Indian private 
sector. The majority of previous research assessing delays in pathways to care was conducted 
among patients treated under the RNTCP in government health centers as their first action in 
seeking care or after referral from other (private) practitioners.4,5 However, more than three-
quarters of our patient sample sought care exclusively from formal private HCPs, and only 11% 
(24/212) ever accessed RNTCP services. We found 84% of patients first consulted a formal 
private HCP, 	  greater than the 30-78% in previous studies in urban setings and lower than the 0-
47% of patients that first consulted a government provider.4,5,12,20,23 Compared to patients treated 
at RNTCP Centers, these patients treated under PPM had higher levels literacy20,23, household 
income4,23, and lived in closer proximity to their first providers.4,20,23 
 
Among these patients who were treated via PPM, the total delays reported were substantialy 
lower than those (>90 days) among patients first seeking private-sector care in a previous study of 
patients ultimately treated by the RNTCP.5 Relative to prior estimates in the literature, health 
system delay in our study was shorter among patients who first consulted formal private HCPs 
but longer among patients who first consulted government HCPs.4,20,23 The majority of these PPM 
patients only saw one or two HCPs, fewer than the median of nearly three in a recent systematic 
review4, suggesting PPM may have reduced the number of providers required to be seen before 
diagnosis.5,73 However, the prolonged delays and multiple visits required prior to TB diagnosis 
are consistent with a recent systematic review on quality of TB care in India41, which showed 
approximately half of HCPs knew that persons with cough lasting 2-3 weeks should be evaluated 
for TB, and two-thirds used smear microscopy for patients with presumptive TB. Although smear 
microscopy and chest x-ray were commonly used in diagnosis, the Indian system of patient 
referral to private labs for testing causes substantial delays during the diagnostic process.52 Usage 
of inappropriate TB diagnostic tests documented among private practitioners in India may further 
contribute to delays in TB diagnosis, development of drug resistance, and ongoing TB 
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transmission.17,41,45 A recent study of standardized patients seeking care for TB symptoms in the 
private sector found that only 5% of private practitioners ordered any sputum testing.74 While 
improved diagnostic tests, including Xpert MTB/RIF, are being scaled up in both public62 and 
private sectors18, use is stil limited. A paralel study of private practitioners in Chennai found that 
only 15% ordered Xpert MTB/RIF for TB diagnosis in the past year.75 
 
Our findings highlight the need to improve diagnostic capacity to reduce delays in the private 
sector as the first point of patient care. Our study was not designed to evaluate specific 
interventions for reducing delays, but modeling analyses suggest that both increased access to 
improved diagnostic tests, such as Xpert MTB/RIF, and increased cross-sector referrals could 
substantialy reduce the number of visits by TB patients that fail to result in TB diagnosis and 
treatment in India.21 Additionaly, a demonstration study implementing Xpert MTB/RIF as the 
initial TB diagnostic test in decentralized public health setings throughout India increased case-
notification rates of al bacteriologicaly confirmed TB.62 The RNTCP and Initiative for 
Promoting Affordable Quality TB Tests are working to increase availability of WHO-approved 
TB diagnostic tests in both public-sector microscopy centers and private laboratories used by 
formal HCPs.17,69 The RNTCP also seeks to engage the private sector through innovative PPM 
schemes, which have increased TB case notification by 12-98% in previous studies of public-
private partnerships in India.8,76,77 By implementing a referral system for informal HCPs and 
giving formal private HCPs access to WHO-approved diagnostics, it may be possible to reduce 
diagnostic delays and thus decrease the burden of TB transmission in the community. Future 
studies should investigate the impact of specific interventions. 
 
As an early investigation into patient pathways to TB diagnosis in the Indian private sector, this 
study has a number of limitations. First, this patient population may not be representative of other 
patients who access the private sector for TB care but are not referred to PPM. Patients that are 
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not referred to PPM remain under private TB treatment may have higher income, greater privacy 
concerns, or less TB knowledge, or providers that are not aware of REACH PPM and thus they 
undergo private treatment. Additionaly, we limited inclusion to patients referred to PPM by 
private practitioners (practicing in standalone private clinics, private hospitals, or private 
hospitals containing REACH PPM Centers) to evaluate patients accessing the private sector in 
Chennai, though REACH receives PPM referrals from other sources.  Our findings may also not 
generalize to patients diagnosed in the public sector 5. Second, similar to most other studies of 
diagnostic delay, our study relied on patient recal for data colection.4 We conducted patient 
interviews within six months of starting TB treatment potentialy affecting patient recal and 
biasing results to over or underestimate the effect of the first provider consulted on total delay, 
though we used calendars and interview reference cards to reduce recal bias in our data. Finaly, 
we did not colect data on smoking or alcohol usage, two known confounders of delay, as our 
interviewers felt this was an invasion of patient privacy that would damage interviewer-patient 
rapport. Future studies should address the chalenges in accessing the private sector to gather 
more representative data on this patient population. 
 
Conclusion 
Our study provides insight about delays in TB diagnosis and treatment among patients who 
received TB care in the Indian private sector. The pathways to care for TB in India are diverse, 
but most patients treated in PPM are linked to care after two HCPs or less in the private sector. 
However, total delays to diagnosis remain substantial. Patients who first seek care in the informal 
private sector do so quickly after symptoms develop, but then experience prolonged health system 
delays. Engaging informal and formal private HCPs to improve their capacity to rapidly diagnose 
TB is critical to reduce total symptomatic time and thus TB transmission. 
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Tables and Figures  
 
Table 2.1. Socio-demographic and care-seeking characteristics of patients with pulmonary 





Total Delay  
>90 days  
 (n=70) 
n(%) P* 
Total Delay  
>150 days  
(n=28) 
n(%)  P* 
Age, median [IQR]  42 [28-53] 42 [27-53] 0.76 38 [28-50] 0.46 
  ≥ 45 years 127 (44) 29 (41) 0.63 10 (36) 0.36 
Male 163 (56) 36 (51) 0.35 12 (43) 0.13 
Education 
       Iliterate 38 (13) 11 (16) 0.69 2 (7) 0.60 
  Literate, less than Primary 40 (14) 7 (10) 
 
4 (14) 
   Primary and/or Secondary 135 (47) 33 (47) 
 
12 (43) 




        Unemployed 43 (15) 13 (19) 0.05 4 (14) 0.60 
   Other 
(Retired/Housewife/Student) 
89 (31) 28 (40) 
 
11 (40) 
    Employed 157 (54) 29 (41) 
 
13 (46) 
 Ave. household income/month 
        < Rs. 4000 38 (13) 9 (13) 0.82 1 (3) 0.31 
   Rs. 4001 - Rs. 8,000 112 (39) 30 (43) 
 
10 (36) 
    Rs. 8,001 - 10,000 64 (22) 13 (19) 
 
7 (25) 
    > Rs. 10,001 75 (26) 18 (25) 
 
10 (36) 
 Cough duration prior to diagnosis, 
median [IQR] 
 30 [28-90] 90 [45-120] <0.001 105 [30-165] 0.01 
   Cough ≥30 days 156 (54) 41 (59) <0.01 14 (50) 0.11 
History of previous TB treatment 38 (13) 7 (10) 0.42 4 (14) 0.77 
Family member ever treated for TB 80 (28) 13 (19) 0.05 9 (32) 0.66 
Site of TB Disease 
        Extra-Pulmonary TB 77 (27) 24 (34) 0.10 13 (46) 0.01 
   Pulmonary TB 212 (73) 46 (66) 
 
15 (54) 
 First Healthcare Sector Consulted 
        Government  18 (6) 6 (8) 0.07 4 (14) 0.18 
   Private  243 (84) 53 (76) 
 
21 (75) 
    Informal or Pharmacy 28 (10) 11 (16) 
 
3 (11) 
 First Healthcare Provider Type 
        Informal  28 (10) 12 (17) 0.02 24 (86) 0.33 
   Formal Alopathic or AYUSH 261 (90) 58 (83) 
 
4 (14) 
 HCPs seen prior to diagnosis, median 
[IQR] 
 2 [1- 2] 2 [2-3] <0.001 2 [2-3] <0.01 
   1 HCP 117 (40) 16 (23) <0.001 5 (18) 0.01 
   2 HCPs 106 (37) 27 (39) 
 
11 (40) 
    3 HCPs 36 (13) 12 (17) 
 
6 (21) 
    ≥4 HCPs 30 (10) 15 (21) 
 
6 (21) 
 Visits to 1st HCP, median [IQR]† 3 [1-5] 3 [2-5] 0.14 4 [3-6] 0.23 
   >2 visits 88 (30) 26 (37) 0.16 11 (39) 0.29 
Distance to 1st HCP, median [IQR]  1 [0- 3] 1 [1-4] 0.26 1 [1-4] 0.43 
   >2 km  73 (25) 23 (33) 0.09 10 (36) 0.18 
Total cost incurred with 1st HCP, 
median [IQR] 
1000 [300-3000] 1500 [500-5000] 0.04 1500 [500-5500] 0.20 
   Less than Rs. 400 88 (30) 16 (23) 0.10 6 (21) 0.36 
   Rs. 401 to Rs. 1000 77 (27) 15 (22) 
 
6 (21) 
    Rs. 1001 to Rs. 3000 57 (20) 17 (24) 
 
6 (21) 
    Greater than Rs. 3000 67 (23) 22 (31) 10 (36) 
*Pearson's chi-squared (or Fisher's exact) test for categorical variables comparing those with ≤90 and >90 days, and 150 days; Wilcoxon test for 
continuous variables.  †Patients were classified as having ≤2 visits to the first HCP if the number of visits was unknown. 
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 Provider Number   
PTB Patients 
n (%)  1  ! 2 ! 3  ! 4 ! 5 
Median Total 
Delay [IQR] Range 
Total n=212 
  
   52 [33-83] (3-341) 
60 (28) PD PPM    50 [28-72] (3-341) 
38 (18) PD PD    57 [40-88] (14-316) 
22 (10) PD     37 [20-83] (7-180) 
21 (10) PD PD PPM   46 [34-69] (13-150) 
10 (5) PD PD PD   54 [30-108] (17-199) 
6 (3) GD PD PPM   56 [31-73] (8-77) 
5 (2) PD PD PD PD  35 [27-71] (21-163) 
5 (2) PD PD PD PPM  54 [51-71] (36-83) 
4 (2) PH PPM    68 [60-117] (60-117) 
3 (1) GD PD    77 [63-170] (63-170) 
3 (1) PD PD GD PD  49 [37-58] (37-58) 
3 (1) PH PD PPM   41 [31-69] (31-69) 
2 (1) PA PD    41 [4-78] (4-78) 
2 (1) PD GD PD PPM  75 [40-110] (40-110) 
2 (1) PD GD PD   174 [25-322] (25-322) 
2 (1) PD GD PPM   31 [22-40] (22-40) 
2 (1) PD PD PD PD PPM 116 [97-135] (97-135) 
2 (1) PH PD PD PD  104 [98-111] (98-111) 
2 (1) PH PD    92 [73-110] (73-110) 
2 (1) T PD PPM   235 [147-323] (147-323) 
2 (1) T PD    109 [73-145] (73-145) 
2 (1) T PPM    25 [19-31] (19-31) 
1 (0.5) GD PD PD   72 -- 
1 (0.5) GD PPM    47 -- 
1 (0.5) PA PPM    59 -- 
1 (0.5) PD PD GD PD PPM 48 -- 
 1 (0.5)‡ PD PD PD PD PD 98 -- 
1 (0.5) PD PD PD PD PD 144 -- 
1 (0.5) PD PH PD PD PD 34 -- 
1 (0.5) PH GD PD PPM  70 -- 
1 (0.5) PH PD PD PPM  176 -- 
1 (0.5)‡ T GD PD PD PD 92 -- 
1 (0.5) T GD PD PPM  63 -- 
1 (0.5) T PD  PD PD PPM 108 -- 
Legend: Each line represents a unique pathway taken by patients to arrive at health facilities with REACH 
PPM Centers. Each box represents a different healthcare provider seen by patients, though each box may 
represent more than one provider encounter. For each provider, multiple encounters were often performed. 
Patients who were diagnosed in a private hospital and then began treatment with the REACH PPM Center 
within the hospital are noted as PD for the final encounter. Patients who were diagnosed by a PD in a separate 
clinic who were then referred to a REACH PPM Center for treatment are noted as PPM for the final encounter. 
Abbreviations: PD= Formal Qualified Private doctor, PPM= REACH Public-Private Mix, GD= Formal 
Qualified Government doctor, PH= Informal Pharmacy, PA= Formal Qualified Private AYUSH, IN= Informal 
unqualified non-medical, Traditional, Other. 
‡Patient pathways show only first 5 HCP encounters for these patients; ful paths were 8 HCPs = PD→ PD→ 
PD→ PD→ PD→ PA→ PD→ PPM; and 6 HCPs = T→ GD→ PD→ PD→ PD→ PPM. 
Figure 2.1. Pathways and days of total delay from symptom onset to TB diagnosis and 
treatment initiation among patients being treated for pulmonary TB at a PPM Center in 
Chennai.
29 
Table 2.2. Predictors of differences in duration of total delay days to diagnosis and treatment initiation among patients with pulmonary 
TB (n=212) in Chennai. 
	  
Characteristic 








Difference in Mean 
Total Delay (95% CI) P 
Adjusted Difference 
in Mean Total Delay 
(95% CI)‡ P 
Age <45 years 111 (52)  48 [30-83] 68.3 (61) Ref 
 
Ref 
    ≥45 years 101 (48)  58 [34-86] 69.1 (55) 0.8 (-6.8 - 8.4) 0.83 -4.1 (-16.1 - 7.9) 0.50 
Female 73 (34)  53 [36-90] 69.7 (55) Ref 
 
Ref 
    Male 139 (66)  51 [32-82] 68.2 (60) -1.5 (-23.4 - 20.4) 0.89 6.1 (-14.3 - 26.6) 0.56 
Education up to Primary 118 (56)  49 [31-78] 66.3 (59) Ref 
 
Ref 
    Secondary or greater 94 (44)  54 [37-93] 71.7 (56) 5.4 (-4.3 - 15.0) 0.28 1.5 (-8.3 - 11.2) 0.77 
Unemployed 80 (38)  64 [36-100]* 79.2 (63) Ref 
 
Ref 
    Employed 132 (62)  48 [31-73] 62.4 (54) -16.7 (-39.8 - 6.3) 0.15 -17.9 (-32.1 - -3.7) 0.01 
Ave. monthly household income <Rs. 8,001 114 (54)  51 [32-88] 68.3 (57) Ref 
 
-- 
    ≥Rs. 8,001 98 (46)  54 [33-78] 69.2 (60) 0.9 (-17.5 - 19.3) 0.92 -- 
 History of TB treatment 34 (16)  54 [36-86] 73.4 (62) 5.6 (-16.7 - 27.9) 0.62 11.1 (-1.3 - 23.5) 0.08 
   No previous TB treatment 178 (84)  51 [32-83] 67.8 (57) Ref 
 
Ref 
 Family member treated for TB 61 (29)  46 [32-71] 62.2 (61) -9.1 (-19.1 - 1.0) 0.08 -4.0 (-16.1 - 8.1) 0.52 
   No family treated for TB 151 (71)  54 [33-94] 71.3 (57) Ref 
 
Ref 
 First healthcare provider informal 22 (10)  73 [63-111]** 96.4 (66) 30.9 (14.2 - 47.6) <0.001 25.8 (9.9 - 41.7) <0.01 
   Formal alopathic or AYUSH 190 (90)  49 [32-78] 65.5 (56) Ref 
 
Ref 
 HCPs seen prior to diagnosis ≤2 165 (78)  48 [31-77]** 63.8 (56) Ref 
 
Ref 
    >2 HCPs 47 (22)  71 [37-108] 85.8 (63) 22.1 (8.8 - 35.4) <0.01 20.3 (5.4 - 35.2) <0.01 
Visits to 1st HCP ≤2 or unknown† 153 (72)  51 [34-78] 65.8 (53) Ref 
 
Ref 
 >2 visits 59 (28)  59 [30-94] 76.3 (69) 10.5 (-7.3 - 28.3) 0.25 7.2 (-7.5 - 22.0) 0.34 
Distance to 1st HCP ≤2 km 159 (75)  53 [33-82] 67.0 (57) Ref 
 
Ref 
    >2 km  53 (25)  49 [33-93] 73.5 (62) 6.5 (-1.5 - 14.6) 0.11 0.6 (-9.2 - 10.3) 0.91 
Total cost for 1st HCP <Rs. 1000 109 (51)  53 [33-77] 63.1 (48) Ref 
 
Ref 
    ≥Rs. 1000 103 (49)  51 [31-97] 74.5 (67) 11.4 (-5.5 - 28.3) 0.18 5.3 (-11.8 - 22.3) 0.54 
‡Adjusted for al other variables with data in this column. 
φMedians assessed using non-parametric Wilcoxon test for equality where *P <0.05, and **P<0.01.  




Legend: Patient delay was defined as the interval between onset of symptoms suggestive of PTB 
and patient’s first contact with an HCP; Health system delay is time from the patient’s first 
contact with any HCP to the initiation of anti-TB treatment; Total delay is time from symptom 
onset to the initiation of anti-TB treatment. Crossbars represent 95% confidence intervals for 
mean delays. Median patient, health system, and total delay for patients first seeking care from: 
public sector practitioners were 10, 44, and 64 days; formal private providers were 10, 26, and 48 
days; informal private providers 9, 72, and 73 days; overal was 10, 30, and 52 days, respectively. 
The 11 patients who first sought care in the public sector were eventualy diagnosed by private 
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Figure 2.2. Distribution of mean patient, health system, and total delays by the first 
healthcare sector consulted after symptom onset among patients with pulmonary TB 
(n=212) in Chennai. 
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Table 2.3. Risk factors for prolonged delay >90 days to diagnosis and treatment initiation 




>90 days  
n (%)  
(n=46)  
>90 Days  
Unadjusted 
RR  
(95% CI) P 
>90 Days  
Adjusted 
RR  
(95% CI)* P 
Age ≥ 45 years 22 (48) 1.1 (0.6 - 1.8) 0.86 0.9 (0.5 - 1.6) 0.66 
Male 29 (63) 0.9 (0.3 - 2.4) 0.83 1.4 (0.5 - 4.3) 0.56 
Education Secondary or greater 23 (50) 1.3 (0.8 - 1.9) 0.25 1.2 (0.7 - 1.9) 0.51 
Employed 22 (48) 0.5 (0.3 - 1.1) 0.09 0.5 (0.2 - 1.0) 0.04 
History of previous TB treatment 7 (15) 1.0 (0.5 - 1.8) 0.94 1.2 (0.9 - 1.5) 0.18 
Family member ever treated for TB 7 (15) 0.4 (0.3 - 0.7) <0.001 0.5 (0.3 - 0.9) 0.02 
Informal first HCP 10 (22) 2.4 (1.6 - 3.8) <0.001 2.5 (1.3 - 4.5) <0.01 
Saw >2 HCPs prior to diagnosis 17 (37) 2.0 (1.4 - 3.0) <0.001 1.7 (1.3 - 2.3) <0.001 
Visited 1st HCP >2 times† 15 (33) 1.3 (0.9 - 1.8) 0.18 1.0 (0.7 - 1.4) 0.97 
Distance to 1st HCP >2 km 14 (30) 1.3 (0.9 - 1.8) 0.17 1.1 (0.7 - 1.8) 0.68 
Total cost for 1st HCP ≥Rs. 1000 29 (63) 1.8 (1.3 - 2.5) <0.001 1.9 (1.4 - 2.5) <0.001 
*Adjusted for al other variables with data in this column. 
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Transition to Chapter III 
 
The previous manuscript demonstrates the extensive diagnostic delays that patients experience 
even when seeking care in the formal private sector in Chennai. Notably, patients who consulted 
an informal provider as their first healthcare contact experienced a significant increase of more 
than three weeks of total delay from symptom onset to TB treatment initiation. The risk of a 
prolonged total delay exceeding 90 days was also significantly increased when an informal 
provider was the first point of care consulted. However, the specific practitioner practices that 
contributed to delays in diagnosis among patients eventualy treated in a public-private mix 
program remain unclear among both informal and formal practitioners in the private sector. A 
further limitation of the previous study is that it fails to link patients with the specific practitioners 
that were consulted on the patient’s pathway to care, thus prohibiting an evaluation of the 
practitioners’ TB management practices. To address these concerns, we surveyed formal, 
qualified, alopathic practitioners practicing in the private sector in Chennai who had seen at least 
one patient with TB in the year prior interview. This cross-sectional study, described in the next 
chapter, examines practitioner-reported diagnostic and treatment practices for new patients with 
active pulmonary TB and benchmarks the appropriateness of these practices against the 
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Chapter III: How do urban Indian private practitioners 
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Abstract  
	  
Setting: Private practitioners are frequently the first point of healthcare contact for patients with 
tuberculosis (TB) in India. Inappropriate TB management practices among private practitioners 
may contribute to delayed TB diagnosis and generate drug resistance. However, these practices 
are not wel understood. We evaluated diagnostic and treatment practices for active TB and 
benchmarked practices against International Standards for TB Care (ISTC) among private 
medical practitioners in Chennai. 
 
Design: A cross-sectional survey of 228 practitioners practicing in the private sector from 
January 2014 to February 2015 in Chennai city who saw at least one TB patient in the previous 
year. Practitioners were randomly selected from both the general community and a list of 
practitioners who referred patients to a public-private mix program for TB treatment in Chennai. 
Practitioners were interviewed using standardized questionnaires.  
 
Results: Among 228 private practitioners, a median of 12 (IQR 4-28) patients with TB were seen 
per year. Of 10 ISTC standards evaluated, the median of standards adhered to was 4.0 (IQR 3.0-
6.0). Chest physicians reported greater median ISTC adherence than other MD and MS 
practitioners (score 7.0 vs. 4.0, P<0.001), or MBBS practitioners (score 7.0 vs. 4.0, P<0.001). 
Only 52% of al practitioners sent >5% of patients with cough for TB testing, 83% used smear 
microscopy for diagnosis, 33% monitored treatment response, and 22% notified TB cases to 
authorities. Of 228 practitioners, 68 reported referring al patients with new pulmonary TB for 
treatment, while 160 listed 27 different regimens; 78% (125/160) prescribed a regimen classified 
as consistent with ISTC. Appropriate Treatment practices differed significantly between chest 
physicians and other MD and MS practitioners (54% vs. 87%, P<0.001). 
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Conclusion: TB management practices in India’s urban private sector are heterogeneous and 
often suboptimal. Private providers must be beter engaged to improve diagnostic capacity and 
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Introduction  
 
India accounts for approximately one-quarter of the world’s 9 milion incident tuberculosis (TB) 
cases every year.1 The TB epidemic in India is complicated by the fragmented healthcare delivery 
system that includes practitioners in the public and private sectors.1,4,5 Although the Government 
of India’s Revised National TB Control Program (RNTCP) provides free TB healthcare services, 
up to 85% of patients experiencing TB-related symptoms in urban Indian setings first seek 
healthcare from private practitioners4,78, and about 50% ultimately get TB treatment outside the 
RNTCP.10,41 
 
Based on the International Standards for TB Care (ISTC)47, India has recently published 
Standards for TB Care in India to ensure quality practices in both private and public sectors.38 
However, usage of inappropriate TB diagnostic and treatment practices, and lack of adherence to 
the ISTC continues to be documented among private practitioners in India10,22,41,45,50, potentialy 
contributing to delays in TB diagnosis, development of drug resistance, and ongoing TB 
transmission.17,41,45 
 
Currently, there are several ongoing efforts to engage and improve the quality of TB care in the 
private sector. These include NGO-led models24 and Private Provider Interface Agency projects 
in select cities37 to engage private practitioners in TB care and the Initiative for Promoting 
Affordable Quality TB Tests (IPAQT) to increase availability of appropriate diagnostic tests in 
private laboratories.17,69 In this context, it is helpful to assess urban private practitioners’ practices 
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Methods  
Seting 
Chennai is the sixth largest city in India with a population of 4.6 milion.71 There are an estimated 
550 hospitals registered in Chennai and approximately 10,000 doctors working in the city, though 
the public-private affiliations are unknown.79 We colaborated with the Resource Group for 
Education and Advocacy for Community Health (REACH) to conduct a cross-sectional survey of 
private medical practitioners (PPs) who saw at least one patient with TB in the past year. 
Established in 1999, REACH is a non-governmental public-private mix (PPM) organization 
collaborating with the Corporation of Chennai to involve PPs in the RNTCP.24 REACH works 
with a network PPs that refer patients with TB to their four PPM Centers, located in private 
hospitals in Chennai, to receive free TB treatment under supervision of REACH staff or 
community supporters. 
 
Sample selection and data colection 
We recruited qualified, alopathic medical practitioners of al specialties working in the urban 
private sector. From January 2014 through February 2015, we enroled consenting PPs from the 
ten 2011 census tract zones in Chennai and conducted interviews using a structured questionnaire. 
To identify PPs for recruitment, we used a listing of al city streets in Chennai to randomly select 
up to 50 street corners per zone. REACH staff started at each selected corner and used a 
structured movement algorithm until an eligible PP was located to recruit a maximum of five PPs 
per health facility and minimum of five PPs per zone. Additionaly, we randomly selected PPs 
from REACH’s database of PPM-referring PPs. Al qualified PPs with formal medical training 
who diagnosed at least one patient with pulmonary TB (PTB) in the year prior to recruitment 
were eligible. After a PP agreed to be interviewed for the study, up to three atempts were made 
to complete the interview. Trained study staff performed the interviews privately in the PPs’ 
offices. Structured interviews lasted approximately 15-20 minutes and colected data on PPs’ 
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socio-demographic information (excluding age, which was deemed potentialy identifiable during 
ethical review), patient volume, TB disease knowledge, diagnostic and treatment practices, 
practitioner-reported intervals between patient presentation, diagnosis, and treatment, and their 
patient referral practices. PPs were asked about the drug regimen that they prescribed for their 
new adult patients of 60 kilograms with PTB using an open-ended format. PPs were subsequently 
asked to give the average total duration of treatment for PTB from a set of standardized responses. 
PP-reported education was used to assess level of training by comparing those with higher levels 
of training (i.e., medical doctor (MD) or master of surgery degree (MS)), to those with 
undergraduate bachelor of medicine and bachelor of surgery degrees (MBBS). We also compared 
chest specialists against those without such specialty training.  
 
International standards for TB care (ISTC) 3rd Edition 
The ISTC include 21 standards of diagnosis, treatment, and other practices that describe a widely 
accepted level of TB care.45,47 We evaluated PP-reported practices against 10 ISTC standards 
(those for which comparative data were colected). An ISTC score was calculated by summing 
the total number of standards for which PP-reported practices agreed with ISTC 
recommendations. For example, a score of seven means the PP reported practices that were in 
accordance with seven of the 10 standards evaluated. 
 
Statistical analysis 
Our primary comparisons were of PPs seeing >12 TB patients per year (versus ≤12), and of MD 
and MS specialty physicians versus MBBS practitioners. We assessed univariate differences in 
proportion using Pearson’s (or Fisher’s exact) test and differences in medians for continuous 
variables using the non-parametric Wilcoxon test. Differences in mean patient volume and mean 
ISTC score were explored using linear regression models with robust standard errors to account 
for clustering within health facilities. We estimated multivariable associations with self-reported 
	  
	   39 
rapid TB diagnosis (≤7 days after patient presentation) using Poisson regression models with 
robust standard errors to give relative risks, as the outcome was not rare and log-binomial models 
failed to converge.72 
 
Ethical considerations 
This study protocol was approved by the Johns Hopkins Bloomberg School of Public Health 
Institutional Review Board, McGil University Health Center Biomedical Research Ethics 
Review Board, and REACH Independent Ethics Commitee. Writen informed consent was 




Practitioner socio-demographic profiles 
Of the 249 eligible private practitioners approached to participate, 228 were interviewed (92% 
participation rate). Among these, 161 (71%) were randomly selected within Chennai city and 67 
(29%) from REACH’s PPM database. The majority of PPs were men (70%) and median practice 
experience was 20 years (IQR 15-30) (Table 1). Over half (60%) of PPs had medical degrees and 
36% had MBBS undergraduate degrees; 17% were chest specialist physicians. Overal, 56% of 
PPs worked in private standalone clinics, 34% in private hospitals, and 10% in both government 
and private healthcare setings. The mean annual patient volume in our sample was 6,387 (median 
6,000 [IQR 4,000-8,000]) and 30 patients with TB (median 12 [IQR 4-28]). Chest physicians saw 
a mean of 92 (95%CI: 59-125) TB patients per year, versus 20 (95%CI: 15-25) among other 
MD/MS physicians, and 14 (95%CI: 8-20) among MBBS practitioners (Fig. 1). Providers who 
saw more than 12 patients with TB per year were more likely to be specialists, have more practice 
experience, work in a private hospital, know about Indian TB policies, initiate TB treatment 
without referral to the public sector, and obtain knowledge about TB from such sources as 
medical journals (Table 1).  
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Diagnostic testing practices 
Sputum smear microscopy was commonly used for diagnosis of active TB (83% (188/228); 
95%CI: 77-87), as was chest X-ray (97% (222/228); 95%CI: 95-99). Practitioners reported using 
non-microbiological tests not generaly recommended for active TB diagnosis as part of their 
diagnostic processsuite including erythrocyte sedimentation rate (ESR) (54% (122/228); 95%CI: 
45-60) and tuberculin skin testing (TST; 45% (103/228); 95%CI: 39-52) (Table 2). Nearly one-
quarter (51/228, 22%) of practitioners reported using only smear and chest X-ray for TB 
diagnosis, while 17% (38/228) used only smear, chest X-ray, and ESR and 17% (39/228) reported 
using only the aforementioned tests plus TST. Molecular testing (e.g., Xpert MTB/RIF) and TB 
culture were much less commonly employed (15% (35/228); 95%CI: 11-20, and 15% (33/228); 
95%CI: 10-19, respectively). Usage of serological antibody tests and IGRAs for diagnosis of 
active PTB was reportedly low among al practitioners (2% (5/228); 95%CI: 0-4, and 6% 
(14/228); 95%CI: 3-9, respectively). Among those practitioners that reported using Xpert and 
culture for TB diagnosis, 83% (29/35) and 55% (18/33) of practitioners, respectively, reported 
sending patients to private labs for diagnostic testing. The majority of practitioners reported 
sending patients to private labs for other diagnostic tests they used including: 57% (107/188) for 
smear, 65% (144/222) for chest X-ray, 70% (85/122) for ESR, 73% (75/103) for TST, and 93% 
(13/14) for IGRAs. Chest physicians and other MD/MS practitioners were more likely to report 
using smear microscopy (86% vs. 75%) and Xpert MTB/RIF (23% vs. 1%) for TB diagnosis than 
MBBS practitioners. 
 
Health system delay and predictors of rapid TB diagnosis  
The mean health system delay from patient presentation to TB diagnosis for patients with PTB 
was 7 days (median 6, range 1-22). Sixty-one percent of PPs reported rapid diagnosis within 7 
days of patient presentation. PPs who used smear as the initial diagnostic test reported an average 
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health system delay of 5 days, compared to 10 days among those who did not use smear at the 
first visit. In a comparison of shorter versus longer PP-reported delays ((≤7 days vs. >7 days) 
from patient presentation to TB diagnosis, the reported use of smear microscopy as the initial 
diagnostic test was the only variable associated with more rapid PP-reported diagnosis, with a 
relative risk of 3.2 (95%CI: 2.3-4.3) for diagnosis within one week.  
 
ISTC and TB treatment practices 
Adherence to the ISTC was generaly inadequate (Table 3) with an overal median ISTC 
adherence score of 4.0 (IQR 3.0-6.0). Among PPs who saw patients with cough lasting >2 weeks 
in the week prior to being interviewed, only 52% sent more than 5% of these patients for TB 
laboratory testing. Only 25% of al PPs used culture or molecular testing for patients with clinical 
suspicion of TB, 33% monitored treatment response, and 22% notified TB cases to public 
authorities. There were no significant differences in use of smear microscopy by patient volume, 
health facility type, or health sector. Chest physicians and other MD/MS practitioners with higher 
levels of training reported greater adherence to al standards except for direct observation of 
treatment (Table 3). Median ISTC scores were significantly higher among chest physicians than 
other MD/MS practitioners (7.0 vs. 4.0, P<0.001), or MBBS practitioners (7.0 vs. 4.0, P<0.001), 
reflecting greater reported adherence (Fig. 2).  
 
Of 228 responding PPs, 160 listed 27 different treatment regimens for PTB, while the other 68 
referred al patients for TB treatment. Prescriptions inconsistent with ISTC included incorrect 
treatment durations (16/160), drug regimens lacking pyrazinamide and/or ethambutol (10/160) or 
including quinolones or injectable second-line agents (10/160). Of 160 PP’s, only 78% prescribed 
a regimen consisting of (a) 6 to 8 months of isoniazid and rifampin, (b) at least one of 
pyrazinamide or ethambutol, and (c) no second-line agents for a hypothetical patient with new 
PTB. Appropriate prescription practices were significantly lower among chest physicians 
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compared to MD/MS practitioners (54% vs. 87%, P<0.001), but not among providers that saw 
over 12 TB patients per year versus those who saw less (80% vs. 77%). Only 40% of PPs utilized 
DOTS-based approaches to ensure treatment adherence, including referral to RNTCP DOTS 
(55/228), REACH PPM (30/228), or both (7/228). One-third of al PPs reported using sputum 




Diagnostic and treatment practices were variable in this study of qualified private practitioners 
who diagnosed at least one patient with TB in the past year in the urban Indian private sector. As 
examples, less than half of surveyed practitioners tested patients with long-lasting cough for TB, 
nearly half used TST as part of their suite of diagnostic tests for active TB, less than one-quarter 
notified patients treated for TB to public health authorities, and over one-fifth used treatment 
regimens that were either too short, lacked critical drugs, or included second-line agents for 
patients with new pulmonary TB. NGO-led efforts to engage PPs in PPM partnerships in 
Chennai24 have emphasized appropriate TB diagnostic practices, including usage of smear 
microscopy. Nonetheless, given that most patients with TB in urban India are diagnosed and 
treated in the private sector, the underutilization of Xpert and low adherence to ISTC highlights 
the need for widespread engagement of private practitioners for adequate TB control. 
 
Prior studies of practitioners in India have consistently documented variable quality of TB care in 
the private sector.10,22,24,41,45,50,80 In a recent systematic review, only half of the healthcare 
providers from both the public and private sectors tested patients with long-lasting cough for 
suspicion of TB, and two-thirds used smear microscopy for patients with presumptive TB.41 Over 
three-quarters of providers in this study prescribed a treatment regimen potentialy consistent with 
ISTC guidelines for new patients with PTB, higher than in other explorations of private sector TB 
treatment practices.10,22,41 Our findings suggest that TB diagnostic, treatment, and notification 
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practices in a randomly recruited sample of urban PPs remain inadequate. These findings are 
particularly concerning given reports of poor treatment outcomes and emerging drug resistance in 
India, especialy in urban areas.41–44 
 
This study is among the first to assess PP practices by patient volume and practitioner specialty.42 
We found that chest specialists and those seeing higher volumes of TB patients had somewhat 
more appropriate diagnostic, treatment, and notification practices, though critical gaps stil remain, 
even with efforts by the RNTCP to make TB a notifiable disease.14,17 We also describe a 
comprehensive evaluation of diagnostic practices and diagnostic delays among urban private 
practitioners, including a strong association between use of sputum smear microscopy for initial 
diagnosis and more rapid treatment initiation. These findings contribute to the growing body of 
evidence in support of stronger dissemination, implementation, and enforcement of the ISTC and 
Standards for TB Care in India for al Indian practitioners. 
 
As a cross-sectional study of PP practices, this study has several important limitations. We 
included only formaly trained qualified practitioners and providers referring to a public-private 
mix organization. While we were thereby able to atain a high response rate, our results are not 
representative of al urban private practitioners providing TB care (including unqualified 
providers and practitioners of alternative health systems) and likely overestimate the quality of 
care provided in Chennai as a whole. We restricted interviews to PPs who had diagnosed at least 
one patient with TB in the past year to reduce recal bias. Further, we used structured 
questionnaires for data colection, which alowed us to colect a larger volume of data in the short 
times available to interview PPs; however, for describing actual practices, vignete-based 
questions may be preferred.42 Lastly, our survey captures PPs’ knowledge and self-reported 
practices, but not actual practice. A recent study from India has used, for the first time, 
standardized patients to overcome this limitation, and has reported poor adherence to standards 
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using this approach showing a wide gap between what providers know, and what they do in real 
practice.74 
 
Our findings emphasize the TB burden and management chalenges to practitioners in the urban 
private sector with several implications for policy. First, TB diagnosis and treatment paterns 
were variable, and while chest physicians and high-volume providers reported greater ISTC 
adherence in some aspects (e.g., use of microbiological tests), they reported lower adherence in 
others (e.g., prescription paterns). This widespread variability in practices highlights the need for 
broad-based education and involvement at al levels of the private sector. Practices in the 
informal sector and among lower-volume providers are expected to be substantialy worse.74 
Second, practitioners who reported the shortest health system delays utilized smear microscopy as 
the initial TB diagnostic test, demonstrating the importance of performing TB-specific 
microbiological tests at the first patient visit to decrease diagnostic delay and TB transmission. 
Finaly, as the RNTCP invests in deploying TB diagnostic tests capable of same-day diagnosis 
such as Xpert, and IPAQT works to increase test availability in private laboratories, mechanisms 
of public-private cross-referral and regulation are essential to engage PPs and link their patients to 
guideline-based TB care.16,63 Modeling analyses suggest that such private-public mechanisms and 
availability of quality diagnostics can have a substantial population-level impact on TB in India.32 
 
Conclusion 
In conclusion, our study shows variability in TB diagnostic and treatment practices in India’s 
urban private sector, including among qualified providers, high-volume providers, chest 
physicians, and those referring to public-private mix organizations for TB treatment. In particular, 
screening of individuals with persistent cough, use of TB-specific tests at the initial encounter, 
expanded use of molecular tests and treatment monitoring, and prescription of appropriate first-
line regimens for PTB should be emphasized. Innovative approaches to TB control in India must 
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include broad-based engagement of the private sector if TB elimination in India is to become a 
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Tables and Figures  
 
Table 3.1. Socio-demographic profile and management practices for al forms of TB among 
private practitioners in Chennai, India (n=228). 
  
Patients Diagnosed with TB 






(n=110) n(%)  
>12 Patients 
(n=118) n(%)  P* 
Male 160 (70) 67 (61) 93 (79) <0.01 
Education 
      MBBS 81 (36) 53 (48) 28 (24) <0.001 
  MS 10 (4) 4 (4) 6 (5) 
   MD 137 (60) 53 (48) 84 (71) 
 Years practicing, median [IQR] 20 [15-30] 20 [12-30] 25 [15-30] 0.03 
Practitioner specialty 
      General medicine 153 (67) 83 (76) 70 (59) <0.001 
  Chest/Pulmonary specialist 39 (17) 6 (5) 33 (28) 
   Other** 36 (16) 21 (19) 15 (13) 
 Type of facility 
      Government with private practice in evening 22 (10) 13 (12) 9 (8) <0.001 
  Private standalone clinic or polyclinic 129 (56) 76 (69) 53 (45) 
   Private hospital or nursing home 77 (34) 21 (19) 56 (47) 
 Action for pulmonary TB diagnosis 
      Refer to RNTCP or PPM DOTS center 97 (42) 55 (50) 42 (36) 0.03 
  Treatment in private sector 131 (58) 55 (50) 76 (64) 
 Knowledge of TB notification requirement*** 214 (94) 99 (90) 115 (98) 0.02 
  Notification training 118 (52) 39 (36) 79 (67) <0.001 
  Notified RNCTP of any TB patients 49 (22) 20 (18) 29 (25) 0.24 
Knowledge of serological antibody test ban 126 (55) 48 (44) 78 (66) <0.001 
Awareness of PPM schemes via RNTCP  81 (35) 37 (34) 44 (37) 0.57 
Source of information on TB*** 
      No sources/not PP's specialty 39 (17) 28 (16) 11 (9) <0.001 
  Journals, books, newspaper, newsleters 82 (36) 36 (33) 46 (39) 0.33 
  Internet 71 (31) 33 (30) 38 (32) 0.72 
  CME or workshop 99 (43) 45 (41) 54 (46) 0.46 
  Medical representative or coleague 25 (11) 15 (14) 10 (9) 0.21 
*Pearson's chi-squared (or Fisher's exact) test for categorical variables comparing practitioners who 
diagnosed 5 patients or less with TB to those who diagnosed more than 5 patients with TB in the past year; 
Wilcoxon test for continuous variables.  
**Other MD and MS practitioner specialties included Obstetrics and gynecology (n=15), Pediatrician 
(n=5), Surgeon (General/Orthopedic/Ophthalmologic) (n=4), Diabetes Specialist (n=6), Ear nose and throat 
(n=2), Oncologist (n=1), and Radiologist (n=1). 
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Legend: Dark bars show the mean (with 95% confidence intervals shown as error bars) number of 
patients for whom a laboratory test was sent specificaly to diagnose TB in the past year, as 
reported by private practitioners with each level of training. Light bars show the mean number of 
people reported to be diagnosed with TB in that year. Data table shows the mean number of total 




	   	   	   	   	  
	  
	  
Figure 3.1. Mean annual volume of patients with tuberculosis (TB) in the past year 
according to practitioner training among private practitioners in Chennai.  
48 
Table 3.2. Diagnostic testing practices according to practitioner specialty type among private practitioners in Chennai, India (n=228). 
	  
  Used in TB diagnosis n(%)  Ordered at first patient visit n(%)  
   
Practitioner Level of Training 
  


























Chest X–Ray 3.2 (4) 222 (97) 36 (92) 106 (98) 80 (99) 0.43 135 (59) 31 (80) 64 (59) 40 (49) 0.03 
Sputum Smear  3.5 (4) 188 (83) 36 (92) 91 (84) 61 (75) 0.04 115 (50) 31 (80) 54 (50) 30 (37) <0.01 
Biopsy or FNAC 1.2 (3) 150 (66) 34 (87) 80 (74) 36 (44) <0.001 108 (47) 31 (80) 53 (49) 24 (30) <0.001 
ESR 3.2 (4) 122 (54) 12 (31) 70 (65) 40 (49) 0.35 68 (30) 9 (23) 41 (38) 18 (22) 0.06 
Mantoux Skin Test  2.4 (4) 103 (45) 12 (31) 50 (46) 41 (51) 0.22 61 (27) 12 (31) 29 (27) 20 (25) 0.60 
Differential or Total Lymphocyte Count 4.1 (4) 71 (31) 8 (21) 45 (42) 18 (22) 0.03 45 (20) 7 (18) 28 (26) 10 (12) 0.04 
MRI or CT Scan 1.1 (4) 53 (23) 17 (44) 26 (24) 10 (12) <0.01 39 (17) 14 (36) 16 (15) 9 (11) 0.07 
Molecular Test (Xpert or PCR) 1.0 (4) 35 (15) 23 (59) 11 (10) 1 (1) <0.001 28 (12) 22 (56) 5 (5) 1 (1) <0.001 
Sputum Culture  1.4 (2) 33 (15) 9 (23) 9 (8) 15 (19) 0.20 25 (11) 7 (18) 7 (7) 11 (14) 0.35 
Ultrasound  0.4 (1) 32 (14) 5 (13) 17 (16) 10 (12) 0.59 24 (11) 5 (13) 13 (12) 6 (7) 0.37 
Drug Susceptibility Testing 0.8 (3) 19 (8) 16 (41) 2 (2) 1 (1) <0.01 17 (8) 14 (36) 2 (2) 1 (1) <0.01 
Interferon Gamma Release Assays  2.8 (4) 14 (6) 3 (8) 7 (7) 4 (5) 0.78 5 (2) 1 (3) 3 (3) 1 (1) 0.66 
Serologic Antibody Tests 1.0 (1) 5 (2) 1 (3) 1 (1) 3 (4) 0.35 2 (1) 0 (0) 1 (1) 1 (1) 0.99 
*Other MD/MS practitioner specialties included Other/unknown (n=61), Obstetrics and gynecology (n=15), General internal medicine (n=11), Pediatrician (n=5), Surgeon 
(General/Orthopedic/Ophthalmologic) (n=4), Diabetes Specialist (n=6), Ear nose and throat (n=2), Oncologist (n=1), and Radiologist (n=1). 
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Table 3.3. Evaluation of private practitioners' practices and concordance with the International Standards for TB Care, Chennai, India. 
	  
  Concordance with ISTC n(%)  
  
 Practitioner Level of Training  











Diagnostic Practices       
ISTC 1: Evaluation of cough lasting ≥2 weeks to 
suspect TB† 
Sends >5% patients with cough >2 weeks for lab 
testing 93 (52) 23 (73) 38 (44) 32 (53) 0.03 
ISTC 2: Evaluation of sputum specimens for those 
with CXR findings suggestive of TB Uses smear and chest x-ray for PTB diagnosis 185 (81) 35 (90) 89 (82) 61 (75) 0.09 
ISTC 3: Assessment of ≥2 sputum specimens for 
microbiological examination  Uses smear for PTB 188 (83) 36 (92) 91 (84) 61 (75) 0.04 
ISTC 4: Examination of appropriate specimens 
(and diagnostic tests) for presumptive EP TB 
Uses biopsy/FNAC to obtain specimens for EP-
TB diagnostic testing 150 (66) 34 (87) 80 (74) 36 (44) <0.001 
ISTC 5: Diagnosis of smear-negative TB based on 
bacterial culture or molecular testing Uses culture or Xpert MTB/RIF for TB diagnosis 57 (25) 25 (64) 16 (15) 16 (20) 0.17 
Treatment and Management Practices       
ISTC 8: Treatment with 2HRZE and 4HR fixed 
doses for new TB patients*Ŧ 
Regimen of H, R, and either Z or E for 6-8 
months for hypothetical patient with new PTB 125 (78) 20 (54) 67 (87) 38 (83) 0.53 
ISTC 9: Patient-centered approach to treatment; 
includes DOTS for treatment administration 
Supported treatment via RNTCP, PPM, or PPM 
Community DOTS reported for PTB 92 (40) 3 (8) 39 (36) 50 (62) <0.001 
ISTC 10: Assessment of patient response to therapy 
for pulmonary TB with sputum microscopy 
Performs treatment monitoring using smear, 
culture, or Xpert MTB/RIF 76 (33) 27 (69) 23 (21) 26 (32) 0.77 
ISTC 11: Drug-resistance testing using molecular 
tests and/or bacterial culture based on patient history 
and risk factors Assesses MDR based on appropriate risk factors  43 (19) 29 (74) 8 (7) 6 (7) <0.001 
Addressing HIV Infection and other Co-morbid Conditions 
     ISTC 14: HIV testing and counseling recommended 
to al patients with suspected TB 
Performs HIV testing done Always or Often for 
TB patients 87 (38) 25 (64) 34 (32) 28 (35) 0.41 
Standards for Public Health 
      
ISTC 21: Al providers must report TB cases and 
treatment outcomes to public health authorities. 
Reports notifying TB cases to RNTCP in the past 
year 49 (22) 16 (41) 16 (15) 17 (21) 0.89 
Mean ISTC score, mean(SD)**Ŧ Sum out of 10 standards evaluated 4.5 (1.9) 6.5 (2.0) 4.0 (1.5) 4.1 (1.8) 0.03 
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Table 3.3. Footnotes: 
*Abbreviations used: Smear= sputum smear microscopy, PTB= pulmonary TB, EP-TB= extrapulmonary TB, FNAC=fine needle aspiration cytology, DOTS= directly observed 
therapy short course. H=isoniazid, R=rifampicin, Z=pyrazinamide, and E=ethambutol, irrespective of whether the regimen was daily or intermitent. 
**Pearson's chi-squared (or Fisher's exact) test for categorical variables comparing chest physicians plus other MD/MS practitioners versus MBBS practitioners in the private 
sector; mean ISTC score assessed using linear regression. 
†Data for 50 private practitioners who did not report seeing any patients with prolonged cough were excluded from evaluation for ISTC1 and considered non-adherent for 
calculation of the ISTC score.  









Legend: Practitioner-reported practices were evaluated against 10 of the International Standards 
for TB Care (ISTC) for which comparative data were colected, and an ISTC score was calculated 
by summing the total number of standards for which reported practices agreed with ISTC 
recommendations. For example, a score of seven means the corresponding practitioner reported 
practices in accordance with seven of the 10 standards that we evaluated. Of 10 standards 
evaluated, the overal median ISTC adherence score was 4.0 (IQR 3.0-6.0). Chest physicians 
reported greater adherence than other MD/MS practitioners with higher levels of training (median 
7.0 vs. 4.0, P<0.001), or MBBS practitioners (7.0 vs. 4.0, P<0.001). Box plots depict the median 
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Figure 3.2. Distribution of aggregate practitioner-reported adherence scores to ten of the 
International Standards for TB Care by practitioner training in the private sector in 
Chennai. 
	  
	   52 
Transition to Chapter IV 
	  
The previous two chapters ilustrate the dichotomy of the patient-provider relationship in TB 
diagnosis and treatment in India. While patient delay in seeking healthcare for TB-related 
symptoms plays a role in delaying TB diagnosis and thus total delay, the varied and inadequate 
TB management practices employed by practitioners in the Indian private sector contribute to 
prolonged health systems delay and total symptomatic time. Practitioners who used sputum smear 
microscopy as the initial TB diagnostic test reported the shortest health systems delays in this 
study, highlighting the importance of TB-specific microbiological tests that can be performed at a 
low cost in lower levels of the healthcare system. However, overal practices for TB diagnosis, 
treatment, and notification among these private providers were suboptimal giving cause for 
concern. Stronger private sector engagement and regulation is crucial to improve diagnostic 
capacity of private providers. TB diagnostic tests that can be used at the point of care to deliver 
same-day clinical are essential to decrease total delay, increase case detection, and reduce 
community TB transmission. The next chapter addresses private practitioners current usage of 
point-of-care tests and their atitudes and priorities for future TB diagnostic assays that may be 
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Chapter IV: Usage of rapid, point-of-care assays by private 
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Abstract  
 
Setting: Private practitioners are frequently the first point of healthcare contact for patients with 
tuberculosis (TB) in India, but their diagnostic practices and preferences are not wel understood. 
As new molecular tests are developed for point-of-care (POC) diagnosis of TB, it is imperative to 
understand existing practices and preferences for POC testing in the Indian private sector.  
 
Objective: To evaluate rapid testing practices and identify priorities for novel POC TB tests 
among private practitioners. 
 
Design: We conducted a cross-sectional survey of 228 practitioners practicing in the private 
sector from January 2014 to February 2015 in Chennai city who saw at least one TB patient in the 
previous year. Practitioners were randomly selected from both the general community and a list 
of practitioners who referred patients to a public-private mix program for TB treatment. We used 
standardized questionnaires to colect data on current practices related to point-of-care diagnosis 
and interest in hypothetical POC tests. 
 
Results: Among 228 private practitioners, about half (48%) utilized any rapid testing in their 
current practice. The most commonly used POC tests were glucose (43%), pregnancy (21%), and 
malaria (5%). Providers using POC tests were more likely to work in hospitals (56% vs. 43%, 
P=0.05) and less likely to be chest specialists (21% vs. 54%, P<0.001). Only half (51%) of 
providers would use a hypothetical POC test for TB that was accurate, equipment-free, and took 
20 minutes to complete. Chest specialists were half as likely to express interest in performing the 
hypothetical POC TB test in-house as other practitioners (aPR 0.5, 95%CI: 0.2-0.9).  
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Conclusion: Interest in POC testing for TB was surprisingly low among practitioners in India’s 
urban private sector, particularly among chest specialty physicians. As novel POC tests for TB 
are developed and scaled up, atention must be paid to integrating these diagnostics into 






























Despite efforts to increase case detection, 3 milion new tuberculosis (TB) cases are not notified 
to national TB programs each year; over one-quarter (27%) of these “missed cases” are estimated 
to occur in India.1,31 Improvements in case detection through increased diagnostic capabilities 
could substantialy reduce the gap between notified cases and estimated incidence.1 In particular, 
a rapid, low cost, accurate diagnostic assay for TB that can be used at the point of care to make 
rapid treatment decisions would be a major advance in efforts to reach these individuals.40 Target 
product profiles for such POC tests have been developed and published.81 
 
The Government of India’s Revised National TB Control Program (RNTCP) provides free TB 
healthcare services; however, up to 85% of patients experiencing TB-related symptoms in urban 
Indian setings first seek healthcare in the private sector.4,5,78 Thus, any efforts to implement novel 
TB diagnostic tests in India (and other similar countries) would need to engage private 
practitioners. As TB control programs worldwide begin to prioritize molecular diagnostics that 
are more sensitive than smear microscopy58, it is imperative to consider the implementation of 
tests for TB that could be deployed at the point-of-care.53,59 
 
A critical element of implementing any novel diagnostic test is to evaluate existing capacity for, 
and acceptability of, the test among those healthcare providers who would be responsible for 
using it.39,53 For example, if primary care providers are already using rapid tests for diseases such 
as malaria and HIV, then they may be more likely to adopt a novel POC TB test in future. In this 
context, we sought to evaluate point-of-care (POC) testing practices and to identify priorities for 








Chennai is the sixth largest city in India with a population of 4.6 milion.71 We colaborated with 
the Resource Group for Education and Advocacy for Community Health (REACH) to perform 
cross-sectional interviews with urban private medical practitioners (PPs) in Chennai. As a non-
governmental public-private mix (PPM) organization, REACH colaborates with Corporation of 
Chennai to involve PPs in the RNTCP.24 Through advocacy and outreach efforts, REACH 
networks with PPs in Chennai that refer patients with TB to REACH’s four PPM Centers located 
in private hospitals. Patients referred to REACH receive free TB treatment with supervision by 
REACH staff or community supporters. 
 
Sample selection and data colection 
From January 2014 through February 2015, we recruited and enroled qualified, alopathic 
medical practitioners of al specialties working in the private sector in Chennai. REACH study 
staff used a structured movement algorithm to recruit a maximum of five PPs per health facility 
and minimum of five PPs in each of Chennai’s ten 2011 census tract zones. We also randomly 
recruited PPs from REACH’s database of PPM-referring PPs. Al consenting, qualified PPs with 
formal medical training who diagnosed at least one patient with pulmonary TB (PTB) in the year 
prior to recruitment were eligible for interview. Up to three atempts were made to complete the 
interview after a PP agreed to participate. The structured interviews, performed privately in the 
PPs’ offices by trained study staff, lasted 15 to 20 minutes and included PP socio-demographic 
information (with the exception of age, which was deemed to be potentialy identifiable during 
ethical review), self-reported education (medical doctor/MD, master of surgery/MS, or bachelor 
of medicine and surgery/MBBS degrees), patient volume, clinical specialty, TB disease 
knowledge, and diagnostic and treatment practices including POC testing practices. Interviewers 
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asked practitioners about POC testing practices for pregnancy, glucose, HIV, TB antibody, 
malaria, syphilis, hepatitis, dengue, and typhoid using reference cards listing the tests.  
 
Priorities for a novel point-of-care test  
As part of the interview, PPs were asked about a hypothetical POC test for TB “that could be 
used to replace the tests that [they] currently use. This test could potentialy be done rapidly in 
[their] clinic, like a pregnancy test or blood glucose test,” and was described as accurate, taking 
20 minutes to perform, and requiring no equipment. PPs were asked if they would perform this 
test in their clinic (versus sending patients out to a lab or not performing it), and about the 
maximum amount they would be wiling to pay to use this POC test for most patients with 
symptoms of TB.  
 
Statistical analysis 
We assessed univariate differences in proportion using Pearson’s (or Fisher’s exact) test. We 
evaluated differences in medians for continuous variables using the non-parametric Wilcoxon test. 
To estimate univariate and multivariable associations with self-reported preference to use a new 
POC test for TB in-house, we used Poisson regression models with robust standard errors to 
calculate prevalence ratios, as the outcome was not rare and log-binomial models failed to 
converge.72 We examined colinearity using variance inflation factors, which were below 1.5 for 




Description of population and point-of-care testing practices 
Among 249 eligible PPs recruited, 228 (92%) completed the interview. Of these, 161 (71%) were 
randomly selected within Chennai city and 67 (29%) were randomly selected from REACH’s 
PPM database. More than half (56%) of PPs worked in private standalone clinics, and 17% were 
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chest specialist physicians (Table 1). The median number of TB patients seen per year was 12 
[IQR 4-28]: 65 [IQR 20-125] among chest specialists versus 8 [IQR 4-20] among other 
practitioners (P<0.001). Just under half (110/228, 48%) of al PPs utilized any POC tests in their 
clinics; these included glucose (43%), pregnancy (21%), malaria (5%), hepatitis (4%), dengue 
(4%), typhoid (4%), and HIV (2%) POC tests. Providers who used POC tests were more likely to 
be women, work in a private hospital, have fewer years of practice experience, and be general 
medicine practitioners or other specialists (Table 1). Among practitioners who used point-of-care 
testing, the median volume was 38 POC tests [IQR 15-100] per month, median turnaround time 
was 5 minutes [IQR 3-5], and median cost to patients was 50 INR [IQR 50-88] per test 
(approximately US$0.79) (Table 2). Support staff or nurses performed 55% (60/110) of POC tests, 
while practitioners interpreted the majority (98/110, 89%) of test results. Only one-quarter 
(27/110, 24%) of PPs kept records of the POC test results.  
 
Barriers for use of hypothetical point-of-care tests 
When asked about major barriers to performing any POC tests in their clinics, chest physicians 
cited time constraints as their primary barrier (69%, versus 40% of other practitioners, P<0.001), 
whereas other practitioners also cited the availability of nearby lab services (56%, versus 21% of 
chest specialists, P<0.001) and the lack of an atached lab (24%, versus 8% of chest specialists, 
P=0.03) (Figure 1). There were no significant differences in the PP-reported chalenges to using 
POC tests by patient volume or current POC test usage. Those PPs working in hospitals were 
substantialy less likely to express concern about lack of lab services compared to those in private 
standalone clinics (39% vs. 57%, P=0.01), though they also reported greater time management 
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Interest in a point-of-care test for TB 
Approximately one-tenth (24/228, 11%) of Ps were not interested in any POC testing for TB 
even for a novel test requiring no equipment that could be completed in 20 minutes, while 38% 
(87/228) would only order a test for TB from a private lab and 51% (117/228) would perform the 
novel POC test in-house. Practitioner specialty was independently associated with interest in POC 
testing in adjusted analyses; chest specialists were half as likely to express interest in performing 
a novel TB POC test in-house as were other practitioners (aPR 0.5, 95% CI: 0.2-0.9) (Table 3). 
Practitioners practicing in private hospitals and PPs who did any POC testing were also more 
likely to opt to use the novel test in-house (aPR 1.3, 95%CI: 1.1-1.7; and aPR 1.8, 95%CI: 1.4-
2.4; respectively).  
 
Key priorities for use of a point-of-care test for TB 
When asked to provide the three most important characteristics of a hypothetical new POC test 
for TB, 96% (195/204) listed accuracy and reliability as one of the top three priorities (Figure 2). 
Low cost was named by 52% (106/204), and 39% (79/204) wanted a test that utilized blood 
samples. PPs were wiling to pay a maximum of 200 INR [IQR 100-500] (approximately 




If future POC tests are to make an important impact in the fight against TB in high-burden 
setings like India, they must be implemented in a way that is consistent with current providers’ 
practices and preferences. This cross-sectional survey of 228 private providers in Chennai 
provides important insight in this regard. Specificaly, only half of practitioners surveyed utilized 
any POC tests as part of their current diagnostic practices, and utilization was particularly low 
among chest physicians – who also saw the largest number of TB patients, were most likely to 
use private labs, and had the least enthusiasm for using a hypothetical new POC test for TB in 
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their clinical practice. These findings suggest that chest physicians, the private lab network, and 
practitioners who do not currently use POC tests may need to be further engaged in India before 
any novel POC test for TB could have maximum impact. 
 
Our results also suggest the types of POC tests for TB that are likely to be most favorably 
received and utilized by qualified Indian PPs. Overwhelmingly, the characteristic voted most 
important to a new POC test was accuracy and reliability, suggesting that providers may 
intrinsicaly not trust POC tests for TB to be accurate. As in other studies80, we also found a 
strong preference for blood rather than sputum as the main sample for TB testing. Rapid test 
usage was higher among our urban sample of qualified, private practitioners, though stil under 
50%, than in a study of predominantly rural Indian primary health care providers where only one-
quarter used POC tests.82 These results highlight differences in POC testing practices in different 
sectors of India’s healthcare system, though wilingness to use POC tests for TB was similar in 
both studies.82 These findings are consistent with those from rapid diagnostic tests (RDTs) for 
malaria where provider uptake of these POC tests varied despite widespread availability.70 
Provider reliance on clinical symptoms and lack of confidence in RDT results versus perceived 
advantages of more familiar tests (i.e., microscopy) posed barriers to clinical usage83–85 and more 
than half of providers continue to prescribe antimalarial medications despite a negative RDT 
result.85,86 Building on these findings, to be successful, novel POC diagnostic tests for TB must 
first show demonstrated accuracy and also be usable in a variety of setings.  
 
Key chalenges to performing POC testing for TB in this study included time constraints, easy 
access to local private labs and lack of an atached lab facility, such that – when asked about a 
hypothetical, novel point-of-care test for TB that was accurate, rapid, and equipment-free – only 
about half of al providers, and less than one-quarter of chest physicians, were interested in using 
the novel test in-house. These barriers and recent qualitative research in India52 reinforce the 
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importance of understanding existing infrastructure chalenges to POC testing and suggest the 
ideal placement for future POC tests in such community labs to ensure completion of the test and 
treat loop for patients with TB. 
 
Although Xpert MTB/RIF has been demonstrated as a feasible point-of-care test in African 
setings65, and as a decentralized test in various Indian setings62,87, it remains a high cost test that 
requires sophisticated equipment.64 Low-cost POC tests for HIV and malaria have transformed 
the management of these diseases, yet the need for POC tests for active pulmonary TB remains 
unmet contributing to delayed diagnoses that fuel the epidemic in high burden countries like 
India.21,59,64 The urine lipoarabinomannan (LAM) lateral flow assay represents a simple, low cost 
diagnostic test that can be used at the point of care, but its niche use is limited to screening for 
HIV-associated pulmonary TB in patients with advanced immunodeficiency, which likely 
represents a smal number of patients in the context of the Indian TB epidemic.39,66 As future 
POC TB diagnostic tests become available that can be integrated more broadly into outpatient 
practice, studies such as this one and others52,82, wil be helpful in guiding implementation. 
 
Several important limitations must be considered in this cross-sectional study. Our sample 
included only formaly trained, qualified practitioners who had diagnosed a case of TB in the past 
year and also sampled from providers referring to a public-private mix organization in Chennai. 
This enabled us to atain a high response rate with less recal bias; however, our results may not 
be representative of al urban private practitioners providing TB care (including unqualified 
providers) in India. We also used structured questionnaires for data colection to alow us to 
colect a larger volume of data in the short times available to interview PPs; however, vignete-
based questions may be preferred for describing actual practices and identifying priorities for 
future diagnostics.41 Additionaly, our survey captured practitioner-reported practices and 
preferences for a hypothetical new TB diagnostic test, but not actual practices (as no such TB test 
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currently exists) or qualitative information on diagnostic priorities. A recent study from India 
using standardized patients to evaluate PP practices has reported a wide gap between what 
providers know and what they do in real practice74, which indicates the need for ongoing empiric 
data colection on practice paterns to beter gauge actual POC test usage.  
  
Our findings underscore several important implications for point-of-care testing for TB in urban 
Indian setings. The low usage and limited interest in POC tests reported by chest physicians 
represents a potential obstacle to implementation among the providers who see the most patients 
with TB. Furthermore, the majority of chest physicians and nearly half of al PPs preferred to 
order a test from a private lab even when it could be performed as a POC test on-site, suggesting 
that a shift in culture wil be required before POC testing for TB wil be widely adopted in the 
Indian private sector. Additionaly, it wil be important to engage smal, local laboratories at the 
community level in India, and take advantage of the strong existing relationships between private 




In conclusion, our study demonstrates variable use and interest in point-of-care testing for TB 
among qualified private practitioners in urban India. To ensure successful uptake of future POC 
tests for TB in urban India, such tests may need to be integrated into the private lab system, and 
chest physicians and providers who do not currently use POC tests may need to be specificaly 
engaged. Accuracy, low physician time demand, low cost, and use of blood samples would al 
help increase the acceptability of such tests. Ultimately, if we are to use POC diagnostics to 
improve case detection and halt TB transmission in India, the practices and preferences of private 
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providers with regard to POC testing must continue to be addressed and beter understood to 
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Tables and Figures  
 
Table 4.1. Study population characteristics among private practitioners comparing point-
of-care (POC) testing practices in Chennai, India (n=228). 
	  














    Male 160 (70) 68 (62) 92 (78) <0.01 
Female 68 (30) 42 (38) 26 (22) 
 Education level 
      MBBS 81 (36) 38 (35) 43 (36) 0.96 
  MS 10 (4) 5 (4) 5 (4) 
   MD 137 (60) 67 (61) 70 (59) 
 Type of facility 
      Government with private practice in evening 22 (10) 8 (7) 14 (12) 0.02 
  Private standalone clinic or polyclinic 129 (56) 55 (50) 74 (63) 
   Private hospital or nursing home 77 (34) 47 (43) 30 (25) 
 Years practicing    
  Median [IQR]  20 [15-30] 20 [14-28] 25 [15-30] 0.02 
Practitioner specialty 
      General medicine 153 (67) 77 (70) 76 (65) <0.001 
  Pulmonary specialist 39 (17) 8 (7) 31 (26) 
   Other‡ 36 (16) 25 (23) 11 (9) 
 Number of patients diagnosed with TB 
annualy 
    ≤12 patients with TB 110 (48) 53 (48) 57 (48) 0.99 
>12 patients with TB 118 (52) 57 (52) 61 (52) 
 Action for pulmonary TB diagnosis 
      Refer to RNTCP or PPM DOTS center 97 (42) 48 (44) 49 (42) 0.75 
  Treatment in private sector 131 (58) 62 (56) 69 (59) 
 Usage of sputum smear microscopy for TB 
    Orders at first patient visit for TB diagnosis 115 (50) 54 (49) 61 (52) 0.69 
Not ordered at first patient visit 113 (50) 56 (51) 57 (48) 
 Knowledge of serological antibody test ban 
    Yes 126 (55) 60 (55) 66 (56) 0.83 
No 102 (45) 50 (46) 52 (44) 
 Source of information on TB† 
      No sources/non-chest specialty 39 (17) 14 (13) 25 (21) 0.09 
  Journals, books, newspaper, newsleters 82 (36) 42 (38) 40 (34) 0.50 
  Internet 71 (31) 38 (35) 33 (28) 0.28 
  CME or workshop 99 (43) 46 (42) 53 (45) 0.64 
  Medical representative or coleague 25 (11) 11 (10) 14 (12) 0.65 
*POC tests utilized included glucose (n=97), pregnancy (n=48), malaria (n=12), hepatitis (n=9), dengue (n=9), typhoid (n=9), and 
HIV (n=4). 
**Pearson's chi-squared (or Fisher's exact) test for categorical variables comparing practitioners that perform point-of-care (POC) 
diagnostic tests in-house versus ordering from a private lab; Wilcoxon test for continuous variables.  
‡Other MD and MS practitioner specialties included Obstetrics and gynecology (n=15), Pediatrician (n=5), Surgeon 
(General/Orthopedic/Ophthalmologic) (n=4), Diabetes Specialist (n=6), Ear nose and throat (n=2), Oncologist (n=1), and 
Radiologist (n=1). 
†Categories are not mutualy exclusive. 
	  
	   66 
Table 4.2. Point-of-care testing practices and preferences among private practitioners 














n(%)  P* 
Practitioner level of training 
    MBBS/MS/MD (Non-chest specialty) 102 (93) 52 (98) 50 (88) 0.06 
MD (Chest/Pulmonary specialty) 8 (7) 1 (2) 7 (12) 
 Type of facility 
    Private hospital or nursing home 55 (50) 20 (38) 35 (61) 0.02 
Private standalone clinic or polyclinic* 55 (50) 33 (62) 22 (39) 
 Number of tests per month 
    Median [IQR]  38 [15-100]  20 [15-55] 75 [30-120] <0.001 
Time to get test results (minutes) 
    Median [IQR]  5 [3-5]  5 [4-5]  5 [3-5] 0.30 
Staff performing test  
    Practitioner/Doctor 50 (45) 29 (55) 21 (37) 0.06 
Support Staff/Nurse 60 (55) 24 (45) 36 (63) 
 Staff interpreting test results  
    Practitioner/Doctor 98 (89) 45 (85) 53 (93) 0.23 
Support Staff/Nurse 12 (11) 8 (15) 4 (7) 
 Cost to patients per test (INR) 
    Median [IQR]  50 [50-88]  50 [50-100]  50 [50-75] 0.12 
Keeps record of test results 
    Yes 27 (25) 31 (58) 52 (91) <0.001 
No 83 (76) 22 (42) 5 (9) 
 Reasons for performing POC tests** 
    Results available immediately  96 (87) 42 (79) 54 (95) 0.14 
Convenience for patients 70 (64) 30 (57) 40 (70) 0.46 
Diagnosis and treatment in same visit 35 (32) 19 (36) 16 (28) 0.02 
More affordable for patients 13 (12) 5 (10) 8 (14) 0.38 
Interested in using novel POC TB test 
    Perform in-house 78 (71) 39 (74) 39 (68) 0.55 
Order from lab 32 (29) 14 (26) 18 (32)  
*Pearson's chi-squared (or Fisher's exact) test for categorical variables comparing practitioners who 
diagnosed 12 patients or less with TB to those who diagnosed more than 12 patients with TB in the past 
year; Wilcoxon test for continuous variables.  
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Practitioner-reported reasons for not performing rapid point-of-care tests in their health facility 
among 228 randomly selected private practitioners in Chennai. Practitioners gave multiple 
responses; thus, response categories are not mutualy exclusive. Figures show the distribution of 
PP-reported chalenges in performing POC tests in-house by practitioners’ specialty and level of 
training. Statisticaly significant differences across specialty and level of training included: time 
constraints (listed by 69% of chest physicians versus 40% of non-chest specialists, P<0.001), 
general interest in POC tests (10% versus 3%, P=0.03), use of nearby lab services (21% versus 
56%, p<0.001) and lack of an atached lab (8% versus 24%, p=0.03). Error bars represent 95% 

































Chest Physicians (n=39) 
Other MD/MS (n=108) 
MBBS (n=81) 
Figure 4.1. Distribution of chalenges in performing point-of-care tests in-house according 
to practitioners’ level of training (n=228). 
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Table 4.3. Prevalence and factors associated with interest in performing point-of-care testing for TB in-house among private practitioners 
in Chennai. 
Characteristic* 
Interested in  
POC in-house  
(n=117/228)  
n/total (%) 
Unadjusted PR  
(95% CI) P** 
Adjusted PR  
(95% CI)* P**‡ 
Gender 
     Male 75/160(47) 0.8 (0.6- 0.9) 0.01 0.9 (0.8- 1.2) 0.61 
Female  42/68 (62) Ref 
 
Ref 
 Years practicing 
     ≤20 years  65/117(56) 1.2 (0.9- 1.6) 0.23 1.1 (0.9- 1.4) 0.33 
>20 years 52/111 (47) Ref 
 
Ref 
 Practitioner level of training 
     MD (Chest/Pulmonary specialty) 9/39(23) 0.4 (0.2- 0.8) <0.01 0.5 (0.2- 0.9) 0.03 
MBBS/MS/MD (Non-chest specialty) 108/139 (57) Ref 
 
Ref 
 Type of facility 
     Private hospital or nursing home  61/99(62) 1.4 (1.1- 1.8) <0.01 1.3 (1.1- 1.7) 0.01 
Private standalone clinic or polyclinic† 56/129 (43) Ref 
 
Ref 
 Number of patients diagnosed with TB annualy 
     >12 patients 60/118(51) 1.0 (0.8- 1.3) 0.88 1.1 (0.8- 1.4) 0.59 
≤12 patients 57/110 (52) Ref 
 
Ref 
 Point-of-care testing practices 
     Any POC diagnostic testing 78/110(71) 2.1 (1.6- 2.8) <0.001 1.8 (1.4- 2.4) <0.001 
No POC testing 39/118 (33) Ref 
 
Ref 
 Usage of sputum smear microscopy for TB 
     Orders at first patient visit for TB diagnosis 54/115(47) 0.8 (0.6- 1.1) 0.23 0.9 (0.7- 1.1) 0.35 
Not ordered at first patient visit 63/113 (56) Ref 
 
Ref 
 Knowledge of serological antibody test ban 
     Yes 61/126(48) 0.9 (0.7- 1.2) 0.38 0.9 (0.7- 1.2) 0.56 
No 56/102 (55) Ref 
 
Ref 
 Action for pulmonary TB diagnosis 
       Refer to RNTCP or PPM DOTS center 70/131(53) 1.1 (0.9- 1.4) 0.46 1.2 (1.0- 1.5) 0.11 
  Treatment in private sector  47/97 (49) Ref 
 
Ref 
 *Abbreviations used include point-of-care testing (POC), prevalence ratio (PR), bachelor of medicine and surgery (MBBS), masterof surgery (MS), medical doctor (MD), Revised 
National TB Program (RNTCP), public-private mix (PPM). ‡Adjusted for al other variables with data in this column. †Includes practitioners who practice in government facilities 




Private practitioners were asked to rank their top three priorities for a hypothetical new rapid TB 
diagnostic test under development that could be used to replace the current TB tests and that 
could potentialy be done rapidly in their clinic, like a pregnancy test or blood glucose test. Dark 
gray bars represent the characteristic ranked as the most important priority by practitioners, light 
gray presents the second most important characteristic, and medium gray the third most important 
characteristic. There were 24 practitioners that were not interested in performing POC testing 








































Figure 4.2. Top three characteristics ranked as priorities by private practitioners for a new 
point-of-care test for TB in Chennai, India.  
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Chapter V: Conclusions 
	  
The previous chapters suggest a number of conclusions regarding private sector pathways 
to TB diagnosis in Chennai, India. First, the paths taken by patients to diagnosis and treatment of 
TB in urban Indian setings are diverse. However, the public-private mix organization operated 
by REACH in Chennai city is a model with the ability to link the majority patients diagnosed in 
the private sector to guideline-based care for TB. Nonetheless, mean delays to TB diagnosis 
exceeded two months, and were longer among those who first sought care from informal 
practitioners. Further engagement of informal and formal private practitioners is critical to 
improve their capacity to recognize and rapidly diagnose TB to reduce total symptomatic time 
and health system delays in particular to impact TB transmission. In this context, there was also 
considerable variability in the TB management practices utilized by practitioners in Chennai’s 
private sector. These inconsistencies extended to a lack of adherence to the International 
Standards for TB Care, including among formal, qualified providers, high-volume providers, 
chest physicians, and those referring to a public-private mix organization. Broad-based 
approaches to engage private practitioners in TB control to ensure appropriate screening, TB-
specific diagnostic testing, treatment monitoring, and prescription of first-line regimens for active 
pulmonary TB are necessary to impact TB incidence. Finaly, the low levels of use and interest in 
point-of-care tests for TB diagnosis, particularly among chest specialists, represent potential 
barriers to implementation of novel diagnostic tests in India. The current private-sector practice of 
ordering diagnostic tests from private laboratories may necessitate an important shift in culture 
for point-of-care testing to be widely adopted. Innovative approaches to TB control must integrate 
future diagnostic tests more broadly into private outpatient practices, while also emphasizing their 
importance for improving case detection and halting TB transmission in India.  
The results of this research present a number of future opportunities for investigation. 
While this study was among the first to characterize patients diagnosed with TB in Chennai’s 
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private sector, future endeavors may to address the chalenges in accessing patients in the Indian 
private sector to gather more representative data from a broader patient population, use medical 
records to validate patient-reported pathways to diagnosis, and link patients being privately 
treated with their private practitioners. The private practitioners included in this study provided 
self-reported TB management practices and preferences for a hypothetical new TB diagnostic test, 
but not actual practices or qualitative information on diagnostic priorities. As such, our findings 
indicate the need for ongoing empiric data colection on practice paterns to beter gauge actual 
test usage, priorities, and interest. Further, this research emphasizes the importance of ongoing 
efforts to develop accurate, rapid, low-cost TB diagnostic tests that wil place minimum burden 
on busy private practitioners, as wel as the need for an improved mechanism to engage and 
communicate with those practitioners managing patients outside of the RNTCP.  
In summary, new diagnostics have the potential to improve case detection and halt TB 
transmission in India, but their application is limited by the pathways to care taken by the patients 
in need and by the practices and preferences of the private providers that they depend on to 
provide an accurate and timely diagnosis. Improvements to the private Indian health system are 
necessary for patients to gain more rapid care for TB-related symptoms, but also for the 
practitioners who remain dependent on these patients for their own livelihood thus driving at least 
in part their diagnostic practices; reforms to benefit both parties are essential in order to decrease 
TB transmission in the community and improve health outcomes. Ultimately, the intricacies of 
the Indian private sector must continue to be addressed and beter understood if the individuals 
who access it are to have “universal access” to TB care, and if TB elimination is to be achieved in 
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